Phenyl urea compounds as nampt modulators

The optimized synthesis of phenyl urea compounds using specific intermediates and rigorous purification methods addresses inefficiencies in yield and purity, resulting in more effective Nampt modulators.

CA3168838CActive Publication Date: 2026-11-03CYTOKINETICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CA3168838
Authority / Receiving Office
CA · CA
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-02-07
Filing Date
2021-02-05
Publication Date
2026-11-03
Estimated Expiration
2041-02-05

AI Technical Summary

Technical Problem

Current methods for synthesizing phenyl urea compounds as Nampt modulators face inefficiencies and limitations in yield and purity, particularly in the production of intermediates and final compounds, which affect their effectiveness as Nampt inhibitors.

Method used

The synthesis involves a series of specific chemical reactions and purifications, including the use of intermediates such as 4-(3-(4-chlorobenzyl)ureido)benzenesulfonyl chloride and 4-(2-oxaspiro[3.5]nonan-7-yl)aniline, followed by coupling reactions to form phenyl urea compounds, with meticulous purification steps like column chromatography and HPLC to achieve high yields and purity.

Benefits of technology

This method enhances the yield and purity of phenyl urea compounds, making them more effective as Nampt modulators by optimizing the synthesis process through careful selection of intermediates and purification techniques.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

DEMANDE OU BREVET VOLUMINEUX LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME. CECI EST LE TOME 2 DE 2 CONTENANT LES PAGES 324 À 596 NOTE: Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS / PATENTS THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE THAN ONE VOLUME THIS IS VOLUME 2 OF 2 CONTAINING PAGES 324 TO 596 NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME : NOTE POUR LE TOME / VOLUME NOTE: Example JJ Synthesis of 4-(3-(4-chlorobenzyl)ureido)benzenesulfonyl chloride (Intermediate 36): Step 1: Preperation of 4-(3-(4-chlorobenzyl)ureido)benzenesulfonic acid (Intermediate 36-a): [Image disponible dans le document PDF, Image available in the PDF document]

[0322] To a stirred mixture of sulfanilic acid (2 g, 11.548 mmol, 1.00 equiv) and DIEA (14.91 g, 115.364 mmol, 9.99 equiv) in isopropyl alcohol (20 mL) was added phenyl N-[(4- chlorophenyl)methyl]carbamate (3.62 g, 13.832 mmol, 1.20 equiv). The resulting mixture was stirred at 80°C for overnight, cooled to r.t., and purified by C<com:Sub>18< / com:Sub> column chromatography, eluted with water(0.05%NH<com:Sub>4< / com:Sub>HCO<com:Sub>3< / com:Sub>) / ACN (20:1) to afford 3.7g of 4-(3-(4- chlorobenzyl)ureido)benzenesulfonic acid as a brown solid. LC / MS (APCI) m / z: 341 <com:Math><semantics>[M+H]<annotation encoding="application / x-tex">[M+H]< / annotation>< / semantics>< / com:Math>. Step 2: Preperation of 4-(3-(4-chlorobenzyl)ureido)benzenesulfonyl chloride (Intermediate 36): [Image disponible dans le document PDF, Image available in the PDF document]

[0323] A solution of 4-({[(4-chlorophenyl)methyl]carbamoyl}amino)benzenesulfonic acid (3.5 g, 10.271 mmol, 1.00 equiv) in thionyl chloride (35 mL) was stirred at 60°C for 30 min under nitrogen atmosphere. The mixture was cooled to r.t., and concentrated under reduced pressure to afford 3.8g of 4-({[(4- chlorophenyl)methyl]carbamoyl}amino)benzenesulfonyl chloride as a yellow oil. LC / MS (APCI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: 359 [M+H]. Example KK Synthesis of 4-(2-oxaspiro[3.5]nonan-7-yl)aniline (Intermediate 37): Step 1: Preperation of 2-oxaspiro[3.5]non-6-en-7-yl trifluoromethanesulfonate (Intermediate 37-a): [Image disponible dans le document PDF, Image available in the PDF document]

[0324] To a flame-dried flask was charged disopropylamine (318 mg, 3.14mmol, 1.1 equiv) and THF (6 mL). After cooling to -30 °C, n-BuLi solution (1.32 mL, 3.13 mmol, 1.09 equiv) was added dropwise and the mixture was slowly warmed to -10 °C over 15 min. It was then cooled to -78 °C before a THF solution of 2-oxaspiro[3.5]nonan-7-one (400 mg, 2.85) mmol, 1.0 equiv) was added dropwise. The deprotonation was kept at -78 °C for 15 min and then taken out from bath for another 15 min. Then the flask was re-cooled to -78 °C, a THF solution of PhNTf<com:Sub>2< / com:Sub> (1.12 g, 3.14 mmol, 1.1 equiv) was added slowly and the reaction was again kept for 15 min at -78 °C and 1 h outside bath. Upon completion, half-saturated NH<com:Sub>4< / com:Sub>Cl solution was added and the aqueous phase was extracted with EtOAc (50 mL * 3). The combined organic phase was dried (MgSO<com:Sub>4< / com:Sub>), filtered, and concentrated to yield the crude vinyl triflate, which was directly used in the next step. LCMS-ESI (POS.) m / z: 273.1 <com:Math><semantics>(M+H)+<annotation encoding="application / x-tex">(M+H)^{+}< / annotation>< / semantics>< / com:Math>. Step 2: Preperation of 7-(4-nitrophenyl)-2-oxaspiro[3.5]non-6-ene (Intermediate 37-b): [Image disponible dans le document PDF, Image available in the PDF document]

[0325] To a solution of 2-oxaspiro[3.5]non-6-en-7-yl trifluoromethanesulfonate (2.85) mmol, 1.0 equiv) and (4-nitrophenyl)boronic acid (714 mg, 4.28 mmol, 1.5 equiv) in dioxane / H<com:Sub>2< / com:Sub>O (10 mL, 3:1) was bubbled with N<com:Sub>2< / com:Sub> for 10 min, followed by the addition of K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (794 mg, 5.71 mmol, 2.0 equiv) and Pd(dppf)Cl<com:Sub>2< / com:Sub> (209 mg, 0.285 mmol, 0.1 equiv). The mixture was stirred at 75 °C for 15 h. Upon completion, half-saturated NH<com:Sub>4< / com:Sub>Cl solution was added and the aqueous phase was extracted with EtOAc (10 mL * 2). The combined organic phase was dried (MgSO<com:Sub>4< / com:Sub>), filtered, concentrated, and purified by flash column chromatography (silica, hexanes / EtOAc = <com:Math><semantics>20 / 1−>3 / 1<annotation encoding="application / x-tex">20 / 1 -> 3 / 1< / annotation>< / semantics>< / com:Math>) to yield the desired product as a yellowish waxy solid (512 mg, 73%). LCMS-ESI (POS.) m / z: 246.1 (M+H)<com:Sup>+< / com:Sup>. <com:Sup>1< / com:Sup>H NMR (400 MHz, Chloroform-d) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.16 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.9 Hz, 2 H), 7.49 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.8 Hz, 2 H), 6.24 (tt, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 3.8, 1.6 Hz, 1 H), 4.53 (d, <com:Math><semantics>J=5.8<annotation encoding="application / x-tex">J = 5.8< / annotation>< / semantics>< / com:Math> Hz, 2 H), 4.47 (d, <com:Math><semantics>J=5.8<annotation encoding="application / x-tex">J = 5.8< / annotation>< / semantics>< / com:Math> Hz, 2 H), 2.61 (dt, <com:Math><semantics>J=4.4<annotation encoding="application / x-tex">J = 4.4< / annotation>< / semantics>< / com:Math>, 2.5 Hz, 2 H), 2.52 (tq, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math>, 2.1 Hz, 2 H), 2.10 (t, <com:Math><semantics>J=6.3<annotation encoding="application / x-tex">J = 6.3< / annotation>< / semantics>< / com:Math> Hz, 2 H). Step 3: Preperation of 4-(2-oxaspiro[3.5]nonan-7-yl)aniline (Intermediate 37): [Image disponible dans le document PDF, Image available in the PDF document]

[0326] To a solution 7-(4-nitrophenyl)-2-oxaspiro[3.5]non-6-ene (110 mg, 0.448, 1.0 equiv) in THF (6 mL) was added Pd / C (33 mg, 10% on wet basis, 30% mass equiv). H<com:Sub>2< / com:Sub> was bubbled through for 3 min. The mixture was stirred at 23 °C for 14 h under H<com:Sub>2< / com:Sub> atmosphere. Upon completion, solid was filtered off and the filtrate was concentrated to yield the aniline (90 mg, 93%). LCMS-ESI (POS.) m / z: 218.1 (M+H)<com:Sup>+< / com:Sup>. Example LL Synthesis of 1-(4-chlorobenzyl)-3-(4-(2-hydroxyethyl)phenyl)urea (Intermediate 38): Step 1: Preperation of 1-(4-chlorobenzyl)-3-(4-(2-hydroxyethyl)phenyl)urea (Intermediate 38): [Image disponible dans le document PDF, Image available in the PDF document]

[0327] To a solution of 2-(4-aminophenyl)ethan-1-ol (1.37 g, 10.0 mmol, 1.0 equiv) in CH<com:Sub>2< / com:Sub>Cl<com:Sub>2< / com:Sub> (20 mL) was added p-chlorobenzyl isocyanate (1.70 g, 10.2 mmol, 1.02 equiv) slowly at 0 °C. The mixture was then stirred vigorously at 23 °C for 1 h. Upon completion, precipitation was filtered and washed by cold CH<com:Sub>2< / com:Sub>Cl<com:Sub>2< / com:Sub> (10 mL) and Et<com:Sub>2< / com:Sub>O (10 mL) to yield 1- (4-chlorobenzyl)-3-(4-(2-hydroxyethyl)phenyl)urea (2.8 g, 92%) as an off-white solid. LCMS-ESI (POS.) m / z: 305.10 (M+H)<com:Sup>+< / com:Sup>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.47 (s, 1 H), 7.39 <com:Math><semantics>(d,J=8.4 Hz,2 H),7.32(d,J=8.4 Hz,2 H),7.29(d,J=8.4 Hz,2 H),7.06(d,J=8.2 Hz,2 H)<annotation encoding="application / x-tex">(d, J = 8.4 \text{ Hz}, 2 \text{ H}), 7.32 (d, J = 8.4 \text{ Hz}, 2 \text{ H}), 7.29 (d, J = 8.4 \text{ Hz}, 2 \text{ H}), 7.06 (d, J = 8.2 \text{ Hz}, 2 \text{ H})< / annotation>< / semantics>< / com:Math> H), 6.59 (t, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 1 H), 4.58 (s, 1 H), 4.27 (d, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 2 H), 3.54 (t, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 2 H), <com:Math><semantics>2.63<annotation encoding="application / x-tex">2.63< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, <com:Math><semantics>2<annotation encoding="application / x-tex">2< / annotation>< / semantics>< / com:Math> H). Example MM Synthesis of 1-(4-(2-bromoethyl)phenyl)-3-(4-chlorobenzyl)urea (Intermediate 39): Preparation of 1-(4-(2-bromoethyl)phenyl)-3-(4-chlorobenzyl)urea (Intermediate 39): [Image disponible dans le document PDF, Image available in the PDF document]

[0328] To a solution of 1-(4-chlorobenzyl)-3-(4-(2-hydroxyethyl)phenyl)urea (Intermediate 38, 500 mg, 1.64 mmol, 1.0 equiv) in THF / CH<com:Sub>2< / com:Sub>Cl<com:Sub>2< / com:Sub> (20 mL, 1:1) was added PPh<com:Sub>3< / com:Sub> (516 mg, 1.97 mmol, 1.2 equiv) and imidazole (167 mg, 2.46 mmol, 2.0 equiv). N- bromosuccinimide (350 mg, 1.97 mmol, 1.2 equiv) was then added at 0 °C. The reaction was stirred at 23 °C for 1 h. Upon completion, a mixed solution of NaHCO<com:Sub>3< / com:Sub> and Na<com:Sub>2< / com:Sub>S<com:Sub>2< / com:Sub>O<com:Sub>3< / com:Sub> was added to quench the reaction. The aqueous phase was extracted by CH<com:Sub>2< / com:Sub>Cl<com:Sub>2< / com:Sub> (5 mL). The combined organic phase was washed with brine, dried (MgSO<com:Sub>4< / com:Sub>), filtered, concentrated, and purified by column chromatography (silica, hexanes / EtOAc, 20:1 ->0:1) to yield 1-(4-(2- bromoethyl)phenyl)-3-(4-chlorobenzyl)urea (200 mg, 33%) as a white solid. LCMS-ESI (POS.) m / z: 367.00 (M+H)<com:Sup>+< / com:Sup>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.55 (s, 1 H), 7.39 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.5 Hz, 2 H), 7.33 (d, <com:Math><semantics>J=5.6<annotation encoding="application / x-tex">J = 5.6< / annotation>< / semantics>< / com:Math> Hz, 2 H), 7.31 (d, <com:Math><semantics>J=5.6<annotation encoding="application / x-tex">J = 5.6< / annotation>< / semantics>< / com:Math> Hz, 2 H), 7.13 (d, <com:Math><semantics>J=8.5<annotation encoding="application / x-tex">J = 8.5< / annotation>< / semantics>< / com:Math> Hz, 2 H), 6.63 <com:Math><semantics>(t,J=6.0 Hz,1 H),4.28(d,J=6.0 Hz,2 H),3.67(t,J=7.3 Hz,2 H),3.03(t,J=7.3 Hz,2 H)<annotation encoding="application / x-tex">(t, J = 6.0 \text{ Hz}, 1 \text{ H}), 4.28 (d, J = 6.0 \text{ Hz}, 2 \text{ H}), 3.67 (t, J = 7.3 \text{ Hz}, 2 \text{ H}), 3.03 (t, J = 7.3 \text{ Hz}, 2 \text{ H})< / annotation>< / semantics>< / com:Math> H). [Image disponible dans le document PDF, Image available in the PDF document]

[0329] To a solution of ethyl 2-(4-aminophenyl)acetate (27.46 g, 153.2 mmol) in DCM (20 mL) at 20 °C was added 4-methoxy benzyl isocyanate (25.0 g, 153.2 mmol) dropwise. The resulting mixture was stirred at room temperature for 4 hours then methanol (10 mL) was added and cooled to 0°C. After 1 hour at 0°C the slurry was filtered providing the desired product (26.7 g, 78.0 mmol, 50.9% yield) as an off-white solid. LCMS-APCI (POS.) m / z: 343.1 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ 8.50 (s, 1H), 7.38 – 7.30 (m, 2H), 7.27 – <com:Math><semantics>7.19 (m, 2H),7.15−7.07 (m, 2H),6.94−6.85 (m, 2H),6.52 (t, J=5.9 Hz, 1H),4.22 (d, J=5.9 Hz, 1H)<annotation encoding="application / x-tex">7.19 \text{ (m, 2H)}, 7.15 - 7.07 \text{ (m, 2H)}, 6.94 - 6.85 \text{ (m, 2H)}, 6.52 \text{ (t, J} = 5.9 \text{ Hz, 1H)}, 4.22 \text{ (d, J} = 5.9 \text{ Hz, 1H)}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>5.4 Hz<annotation encoding="application / x-tex">5.4 \text{ Hz}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2H<annotation encoding="application / x-tex">2H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>4.06 (q, J=7.1 Hz<annotation encoding="application / x-tex">4.06 \text{ (q, J} = 7.1 \text{ Hz}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2H<annotation encoding="application / x-tex">2H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>3.73 (s, 3H)<annotation encoding="application / x-tex">3.73 \text{ (s, 3H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>3.55 (s, 2H)<annotation encoding="application / x-tex">3.55 \text{ (s, 2H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1.17 (t, J=7.1 Hz, 3H)<annotation encoding="application / x-tex">1.17 \text{ (t, J} = 7.1 \text{ Hz, 3H)}< / annotation>< / semantics>< / com:Math>.

[0330] Compounds in the following table were prepared in a similar manner as Compound 331, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 2 Synthesis of ({4-[2-(3,3-difluoroazetidinyl)-2-oxoethyl]phenyl}amino)-N-[(4- methoxyphenyl)methyl]carboxamide (Compound 320) [Image disponible dans le document PDF, Image available in the PDF document]

[0331] To a room temperature solution of Intermediate 1.1 (100 mg, 0.318 mmol, 1.0 equiv), 3,3-difluoroazetidine (59 mg, 0.636 mmol, 2.0 equiv) and O-(benzotriazol-1-yl)- N,N,N',N'-tetramethyluronium hexafluorophosphate (181 mg, 0.275 mmol, 1.5 equiv) in dimethylformamide (6 mL) was added N,N-diisopropylethylamine (0.006 mL, 0.03 mmol, 0.1 equiv). The resulting mixture was stirred at room temperature for approximately 9 hours. Resultant reaction mixture was diluted with water (0.5 mL) and extracted with ethyl acetate (2 x 1 mL). The organic phase was dried to a viscous oil which was purified by reverse phase HPLC with a 10%-100% acetonitrile in water solution that was run over 30 minutes in a Phenomonex Gemini 5u C18 column, providing Compound 320 (37.0 mg, 0.095 mmol, 29.9% yield) as a white foam. LCMS-APCI (POS.) m / z: 390.0 (M+H)+. 1H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.46 (s, 1H), 7.37 – 7.29 (m, 2H), 7.27 – 7.18 (m, 2H), 7.12 – 7.04 (m, 2H), <com:Math><semantics>6.94−6.85<annotation encoding="application / x-tex">6.94 - 6.85< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>6.49<annotation encoding="application / x-tex">6.49< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=5.9<annotation encoding="application / x-tex">J = 5.9< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>4.61<annotation encoding="application / x-tex">4.61< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=12.5<annotation encoding="application / x-tex">J = 12.5< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>4.33−4.18<annotation encoding="application / x-tex">4.33 - 4.18< / annotation>< / semantics>< / com:Math> (m, 4H), 3.73 (s, 3H).

[0332] Compounds in the following table were prepared in a similar manner as Compound 320, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 3 Synthesis of N-{4-[(cyclobutylcarbonylamino)methyl]phenyl}{[(4- methoxyphenyl)methyl]amino}carboxamide (Compound 221) [Image disponible dans le document PDF, Image available in the PDF document]

[0333] A scintillation vial was charged with cyclobutanecarboxylic acid (42 mg, 0.63 mmol, 1.0 equiv) and O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (320 mg, 0.84 mmol, 2.0 equiv) in dimethylformamide (2 mL). N, N- diisopropylethylamine was added (37 µL, 0.21 mmol, 0.5 equiv). 1-(4- (Aminomethyl)phenyl)-3-(4-methoxybenzyl)urea (180 mg, 0.63 mmol, 1.5 equiv) was added and the resulting mixture was stirred at room temperature for approximately 30 minutes. Resultant reaction mixture was diluted with water (5 mL) and extracted with ethyl acetate (2 x 8 mL). The organic phase was dried to a viscous oil which was purified by reverse phase HPLC with a 10%-100% acetonitrile in water solution that was run over 30 minutes in a Phenomonex Gemini 5u C18 column, providing the desired product (38.0 mg, 0.10 mmol, 25% yield) as a white solid. LCMS-APCI (POS.) m / z: 368.15 (M+H)+. 1H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.45 (s, 1H), 7.33 (d, J = 8.0 Hz, 2H), 7.23 (d, J = 8.0 Hz, 2H), 7.08 (d, J = 8.1 Hz, 2H), <com:Math><semantics>6.90<annotation encoding="application / x-tex">6.90< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>6.48<annotation encoding="application / x-tex">6.48< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>4.18<annotation encoding="application / x-tex">4.18< / annotation>< / semantics>< / com:Math> (dd, <com:Math><semantics>J=22.4<annotation encoding="application / x-tex">J = 22.4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>5.9<annotation encoding="application / x-tex">5.9< / annotation>< / semantics>< / com:Math> Hz, 4H), <com:Math><semantics>3.74<annotation encoding="application / x-tex">3.74< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=1.5<annotation encoding="application / x-tex">J = 1.5< / annotation>< / semantics>< / com:Math> Hz, <com:Math><semantics>3H<annotation encoding="application / x-tex">3H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>3.04<annotation encoding="application / x-tex">3.04< / annotation>< / semantics>< / com:Math> (p, <com:Math><semantics>J=8.6<annotation encoding="application / x-tex">J = 8.6< / annotation>< / semantics>< / com:Math> Hz, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>2.14<annotation encoding="application / x-tex">2.14< / annotation>< / semantics>< / com:Math> (p, <com:Math><semantics>J=9.4<annotation encoding="application / x-tex">J = 9.4< / annotation>< / semantics>< / com:Math> Hz, <com:Math><semantics>2H<annotation encoding="application / x-tex">2H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>2.02<annotation encoding="application / x-tex">2.02< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=9.4<annotation encoding="application / x-tex">J = 9.4< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>1.88<annotation encoding="application / x-tex">1.88< / annotation>< / semantics>< / com:Math> (q, <com:Math><semantics>J=9.1<annotation encoding="application / x-tex">J = 9.1< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>1.76<annotation encoding="application / x-tex">1.76< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=10.0<annotation encoding="application / x-tex">J = 10.0< / annotation>< / semantics>< / com:Math> Hz, 2H).

[0334] Compounds in the following table were prepared in a similar manner as Compound 221, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 4 Synthesis of 1-(4-((4-(2-hydroxy-2-methylpropyl)piperazin-1-yl)methyl)phenyl)-3-(4- methoxybenzyl)urea (Compound 242) [Image disponible dans le document PDF, Image available in the PDF document]

[0335] To a solution of amine and Intermediate 3.1 (100 mg, 0.35 mmol) and 2-methyl-1- (piperazin-1-yl)propan-2-ol (82 mg, 0.52 mmol) in DCE (2 mL) and pyridine (0.2 mL), preheated at 70 °C for 15 mins and subsequently cooled to room temperature, was added sodium triacetoxyborohydride (112 mg, 0.52 mmol) and the solution was stirred at 50 C for 12 h. The solution was cooled to room temperature and saturated aqueous sodium carbonate solution (3.0 mL) was added and the solution stirred vigorously for 10 mins. The organic layer was separated and the aqueous layer was extracted with 5 mL of DCM. The combined organic layer was washed with brine, dried, filtered, and concentrated. The crude was purified by reverse phase HPLC with a 10%-100% acetonitrile in water solution that was run over 30 minutes in a Phenomonex Gemini 5u C18 column, providing 1-(4-((4-(2-hydroxy-2- methylpropyl)piperazin-1-yl)methyl)phenyl)-3-(4-methoxybenzyl)urea (82 mg, 0.19 mmol) as a viscous pale yellow oil. LCMS-APCI (POS.) m / z: 427.2 (M+H)<com:Sup>+< / com:Sup>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.47 (s, 1H), 7.33 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.1 Hz, 2H), 7.23 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.1 Hz, 2H), 7.12 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.0 Hz, 2H), 6.90 (d, <com:Math><semantics>J=8.2<annotation encoding="application / x-tex">J = 8.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 6.50 (t, <com:Math><semantics>J=5.9<annotation encoding="application / x-tex">J = 5.9< / annotation>< / semantics>< / com:Math> Hz, 2H), 4.22 (d, <com:Math><semantics>J=5.8<annotation encoding="application / x-tex">J = 5.8< / annotation>< / semantics>< / com:Math> Hz, 2H), 3.73 (s, 3H), 3.30 (s, 5H), 2.34 (s, 4H), 2.18 (s, 2H), 1.07 (s, 6H).

[0336] Compounds in the following table were prepared in a similar manner as Compound 242, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 5 Synthesis of [(4-{(1S)-1-[benzylamino]ethyl}phenyl)amino]-N-[(4- chlorophenyl)methyl]carboxamide (Compound 40) [Image disponible dans le document PDF, Image available in the PDF document]

[0337] To a solution of benzaldehyde (58 mg, 0.54 mmol, 1.1 equiv) and (S)-1-(4-(1- aminoethyl)phenyl)-3-(4-chlorobenzyl)urea (150 mg, 0.49 mmol, 1.0 equiv) in dichloroethane (2 mL), stirred at room temperature for 1 hour, was added sodium triacetoxyborohydride (209 mg, 0.99 mmol, 2.0 equiv). The resulting solution was stirred at room temperature for 24 hours. A saturated aqueous sodium carbonate solution (3.0 mL) was added and the solution stirred vigorously for 10 mins. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (30 mL). The combined organic layer was washed with brine, dried, filtered, and concentrated under reduced pressure. The crude was purified by reverse phase HPLC with a 10%-100% acetonitrile in water solution that was run over 30 minutes in a Phenomonex Gemini 5u C18 column, providing the desired product (17 mg, 0.04 mmol, 9% yield) as a white solid. LCMS-LCMS-ESI (POS.) m / z: 396.10 (M+H)+. 1H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.58 (s, 1H), 8.18 (s, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.42 – <com:Math><semantics>7.29 (m, 6H)<annotation encoding="application / x-tex">7.29 \text{ (m, 6H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7.20 (t, J=8.5 Hz, 3H)<annotation encoding="application / x-tex">7.20 \text{ (t, J} = 8.5 \text{ Hz, 3H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7.09 (d, J=7.6 Hz, 1H)<annotation encoding="application / x-tex">7.09 \text{ (d, J} = 7.6 \text{ Hz, 1H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>6.66 (s, 1H)<annotation encoding="application / x-tex">6.66 \text{ (s, 1H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>4.28 (d, J=5.9 Hz)<annotation encoding="application / x-tex">4.28 \text{ (d, J} = 5.9 \text{ Hz)}< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>3.71<annotation encoding="application / x-tex">3.71< / annotation>< / semantics>< / com:Math> (q, <com:Math><semantics>J=6.6<annotation encoding="application / x-tex">J = 6.6< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>3.59<annotation encoding="application / x-tex">3.59< / annotation>< / semantics>< / com:Math> (s, 2H), <com:Math><semantics>2.43<annotation encoding="application / x-tex">2.43< / annotation>< / semantics>< / com:Math> (s, 3H), <com:Math><semantics>1.29<annotation encoding="application / x-tex">1.29< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.5<annotation encoding="application / x-tex">J = 6.5< / annotation>< / semantics>< / com:Math> Hz, 3H).

[0338] Compounds in the following table were prepared in a similar manner as Compound 40, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 6 Synthesis of N-[(4-chlorophenyl)methyl]({4- [(methylsulfonyl)methyl]phenyl}amino)carboxamide (Compound 136) [Image disponible dans le document PDF, Image available in the PDF document]

[0339] To a room temperature solution of N,N'-disuccinimidyl carbonate (553 mg, 2.16 mmol, 1.0 equiv) in acetonitrile (10 mL) was added 4-(methanesulfonylmethyl)aniline (0.40 g, 2.16 mmol, 1.0 equiv) followed by pyridine (0.174 mL, 2.16 mmol, 1.0 equiv) in a dropwise fashion. After 20 minutes, a solution 4-chloro benzyl amine (290 mg, 2.05 mmol, 0.95 equiv) in acetonitrile (2 mL) was added followed by N,N-diisopropylethylamine (0.752 mL, 4.32 mmol, 2.0 equiv). The resulting mixture was stirred at room temperature for approximately one hour then concentrated to dryness. Resultant mixture was diluted with ethyl acetate (50 mL) and extracted with water (2 x 15 mL) and brine (1 x 15 mL). The organic phase was dried to a viscous oil which was crystallized from dichloromethane and diethyl ether. Slurry was filtered to afford N-[(4-chlorophenyl)methyl]({4- [(methylsulfonyl)methyl]phenyl}amino)carboxamide as a white solid (362 mg, 1.03 mmol, 50% yield). LCMS-APCI (POS.) m / z: 353.0 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ <com:Math><semantics>8.72<annotation encoding="application / x-tex">8.72< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>7.47−7.34<annotation encoding="application / x-tex">7.47 - 7.34< / annotation>< / semantics>< / com:Math> (m, 4H), <com:Math><semantics>7.38−7.28<annotation encoding="application / x-tex">7.38 - 7.28< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>7.31−7.21<annotation encoding="application / x-tex">7.31 - 7.21< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>6.70<annotation encoding="application / x-tex">6.70< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=6.1<annotation encoding="application / x-tex">J = 6.1< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>4.36<annotation encoding="application / x-tex">4.36< / annotation>< / semantics>< / com:Math> (s, 2H), <com:Math><semantics>4.29<annotation encoding="application / x-tex">4.29< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>2.85<annotation encoding="application / x-tex">2.85< / annotation>< / semantics>< / com:Math> (s, 3H).

[0340] Compounds in the following table were prepared in a similar manner as Compound 136, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 7 Synthesis of N-(4-{2-[(3S)-3-(hydroxymethyl)piperazinyl]-2-oxoethyl}phenyl){[(4- fluorophenyl)methyl]amino}carboxamide (Compound 181) [Image disponible dans le document PDF, Image available in the PDF document]

[0341] 2,2,2-Trifluoroacetic acid (1 mL) was added to a solution of tert-butyl (2R)-4-{2- [4-({[(4-chlorophenyl)methyl]amino}carbonylamino)phenyl]acetyl}-2- (hydroxymethyl)piperazinecarboxylate (150 mg, 0.30 mmol, 1.0 equiv) in methylene chloride (5 mL), dropwise. The resulting mixture was stirred at room temperature for approximately 3 hours. Resultant reaction mixture was dried and the resulting residue was purified by reverse phase HPLC with a 10%-100% acetonitrile in water solution that was run over 30 minutes in a Phenomonex Gemini 5u C18 column, providing the desired product (92.0 mg, 0.23 mmol, 77% yield) as a white solid. LCMS-ESI (POS.) m / z: 401.10 (M+H)+. 1H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.87 (s, 1H), 8.59 (s, 1H), 7.34 (t, J = 7.4 Hz, 3H), 7.16 (t, J = 8.7 Hz, 2H), 7.08 <com:Math><semantics>(d,J=8.1 Hz,2H),6.68(t,J=6.0 Hz,1H),5.55−5.41(m,1H),4.44−4.32(m,1H),4.27<annotation encoding="application / x-tex">(d, J = 8.1 \text{ Hz}, 2H), 6.68 (t, J = 6.0 \text{ Hz}, 1H), 5.55 - 5.41 (m, 1H), 4.44 - 4.32 (m, 1H), 4.27< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(d,J=5.9Hz,2H),4.17−3.93(m,2H),3.78−3.57(m,3H),3.53(dd,J=11.4,5.6Hz,1H),<annotation encoding="application / x-tex">(d, J = 5.9 Hz, 2H), 4.17 - 3.93 (m, 2H), 3.78 - 3.57 (m, 3H), 3.53 (dd, J = 11.4, 5.6 Hz, 1H),< / annotation>< / semantics>< / com:Math> <com:Math><semantics>3.18<annotation encoding="application / x-tex">3.18< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=3.8<annotation encoding="application / x-tex">J = 3.8< / annotation>< / semantics>< / com:Math> Hz, <com:Math><semantics>2H<annotation encoding="application / x-tex">2H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>3.14<annotation encoding="application / x-tex">3.14< / annotation>< / semantics>< / com:Math> (s, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>2.98−2.68<annotation encoding="application / x-tex">2.98 - 2.68< / annotation>< / semantics>< / com:Math> (m, <com:Math><semantics>2H<annotation encoding="application / x-tex">2H< / annotation>< / semantics>< / com:Math>).

[0342] Compounds in the following table were prepared in a similar manner as Compound 181, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 8 Synthesis of N-{4-[(1S)-1-(methylsulfonyl)ethyl]phenyl}{[(4- chlorophenyl)methyl]amino}carboxamide (Compound 86) and N-{4-[(1R)-1- (methylsulfonyl)ethyl]phenyl}{[(4-chlorophenyl)methyl]amino}carboxamide (Compound 127) [Image disponible dans le document PDF, Image available in the PDF document] Step 1: Preparation of N-{4-[-1-(methylsulfonyl)ethyl]phenyl}{[(4- chlorophenyl)methyl]amino}carboxamide [Image disponible dans le document PDF, Image available in the PDF document]

[0343] To a stirred solution of 4-(1-methanesulfonylethyl)aniline (300.00 mg, 1.505 mmol, 1.00 equiv) and phenyl N-[(4-chlorophenyl)methyl]carbamate (472.80 mg, 1.807 mmol, 1.20 equiv) in acetonitrile / THF (4 mL / 2mL) was added TEA (457.02 mg, 4.516 mmol, 3.00 equiv) at r.t. The resulting mixture was stirred at 60oC for overnight, then concentrated under reduced pressure, purified by Prep-HPLC with the following conditions (Column: XBridge Prep OBD C18 Column 30×150mm 5um; Mobile Phase A:Water(10MMOL / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 35% B to 35% B in 10 min; 254 nm; Rt: 9.68 min) to afford 3-[(4-chlorophenyl)methyl]-1- -[4-(1-methanesulfonylethyl)phenyl]urea (90 mg, 16.30%) as a white solid. LRMS (ES) m / z 367[M+H]. Step 2: Preparation of N-{4-[(1S)-1-(methylsulfonyl)ethyl]phenyl} {[(4- chlorophenyl)methyl]amino}carboxamide (Compound 86) and N-{4-[(1R)-1- (methylsulfonyl)ethyl]phenyl} {[(4-chlorophenyl)methyl]amino}carboxamide (Compound 127) [Image disponible dans le document PDF, Image available in the PDF document]

[0344] The racemic compound 3-[(4-chlorophenyl)methyl]-1-[4-(1- methanesulfonylethyl)phenyl]urea(90 mg, 0.257 mmol, 1.00 equiv) was separated by Chiral- HPLC with the following conditions(Column: CHIRALPAK<com:Sup>TM< / com:Sup> IA, 2*25cm,5um;Mobile Phase A:Hex(8mmol / L NH3.MeOH)--HPLC, Mobile Phase B: EtOH--HPLC; Flow rate: 16 mL / min; Gradient: 50 B to 50 B in 20 min; 220 / 254 nm) to afford 33.9 mg 3-[(4-chlorophenyl)methyl]- 1-[4-[(1S)-1-methanesulfonylethyl]phenyl]urea and 39.9 mg 3-[(4-chlorophenyl)methyl]-1-[4- [(1R)-1-methanesulfonylethyl]phenyl]urea as white solids. The chiral analytical data shows retention times of (RT: 10.53 min) and (RT: 15.92 min) for the first and second peak respectively. The first peak was arbitrarily assigned as (S)-1-(4-chlorobenzyl)-3-(4-(1- (methylsulfonyl)ethyl)phenyl)urea and second peak was assigned as (R)-1-(4-chlorobenzyl)-3- (4-(1-(methylsulfonyl)ethyl)phenyl)urea. Enantiomer 1: LRMS (ES) m / z 367 [M+H]. 1H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.74 (s, 1H), 7.41 (dd, J = 12.3, 8.2 Hz, 4H), 7.31 (t, J = 8.1 Hz, 4H), <com:Math><semantics>6.71<annotation encoding="application / x-tex">6.71< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>4.42<annotation encoding="application / x-tex">4.42< / annotation>< / semantics>< / com:Math> (q, <com:Math><semantics>J=7.1<annotation encoding="application / x-tex">J = 7.1< / annotation>< / semantics>< / com:Math> Hz, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>4.29<annotation encoding="application / x-tex">4.29< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=5.9<annotation encoding="application / x-tex">J = 5.9< / annotation>< / semantics>< / com:Math> Hz, <com:Math><semantics>2H<annotation encoding="application / x-tex">2H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>2.77<annotation encoding="application / x-tex">2.77< / annotation>< / semantics>< / com:Math> (s, <com:Math><semantics>3H<annotation encoding="application / x-tex">3H< / annotation>< / semantics>< / com:Math>), 1.59 (d, J = 7.1 Hz, 3H). Enantiomer 2: LRMS (ES) m / z 367[M+H]. 1H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.74 (s, 1H), 7.46 – 7.36 (m, 4H), 7.31 (t, J = <com:Math><semantics>8.5 Hz<annotation encoding="application / x-tex">8.5 \text{ Hz}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>4H<annotation encoding="application / x-tex">4\text{H}< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>6.71 (t, J=6.0 Hz<annotation encoding="application / x-tex">6.71 \text{ (t, J} = 6.0 \text{ Hz}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1H<annotation encoding="application / x-tex">1\text{H}< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>4.42 (q, J=7.1 Hz<annotation encoding="application / x-tex">4.42 \text{ (q, J} = 7.1 \text{ Hz}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1H<annotation encoding="application / x-tex">1\text{H}< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>4.29 (d, J=5.9 Hz<annotation encoding="application / x-tex">4.29 \text{ (d, J} = 5.9 \text{ Hz}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2H<annotation encoding="application / x-tex">2\text{H}< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>2.77 Hz<annotation encoding="application / x-tex">2.77 \text{ Hz}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(s,3H),1.59(d,J=7.1Hz,3H).<annotation encoding="application / x-tex">(s, 3H), 1.59 (d, J = 7.1 Hz, 3H).< / annotation>< / semantics>< / com:Math>

[0345] Compounds in the following table were prepared in a similar manner as Compounds 86 and 127, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 9 [Image disponible dans le document PDF, Image available in the PDF document]

[0346] Methanesulfonyl chloride (21µL, 0.269 mmol, 1.3 equiv) was added to a stirring solution of 1-(4-(aminomethyl)phenyl)-3-(4-chlorobenzyl)urea hydrochloride (60 mg, 0.21 mmol, 1 equiv) and diisopropylethylamine (72 µL, 0.41 mmol, 2 equiv) in DMF (2 mL) at rt. After 1 h, the product was isolated by reverse phase HPLC (5->95% MeCN / H<com:Sub>2< / com:Sub>O w / 0.1% formic acid) as a white solid (20 mg, 26%). LCMS-ESI (POS.) m / z: 368.0 (M+H)+. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.60 (s, 1H), 7.44 (t, <com:Math><semantics>J=6.2<annotation encoding="application / x-tex">J = 6.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.38 (t, <com:Math><semantics>J=8.3<annotation encoding="application / x-tex">J = 8.3< / annotation>< / semantics>< / com:Math> Hz, 4H), 7.32 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.19 (d, <com:Math><semantics>J=8.5<annotation encoding="application / x-tex">J = 8.5< / annotation>< / semantics>< / com:Math> Hz, 2H), 6.65 (t, <com:Math><semantics>J=6.1<annotation encoding="application / x-tex">J = 6.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 4.28 (d, <com:Math><semantics>J=5.9<annotation encoding="application / x-tex">J = 5.9< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>4.05<annotation encoding="application / x-tex">4.05< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.3<annotation encoding="application / x-tex">J = 6.3< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>2.81<annotation encoding="application / x-tex">2.81< / annotation>< / semantics>< / com:Math> (s, 3H).

[0347] Compounds in the following table were prepared in a similar manner as Compound 475, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 10 Synthesis of tert-butyl 4-(4-(3-(4-chlorobenzyl)ureido)benzyl)-3-oxopiperazine-1-carboxylate. [Image disponible dans le document PDF, Image available in the PDF document] ~

[0348] To a stirred solution of tert-butyl 3-oxopiperazine-1-carboxylate (162.00 mg, 0.809 mmol, 1.00 equiv) in DMF (3.00 mL) at 0°C was added NaH (38.83 mg, 0.971 mmol, 1.20 equiv, 60%). After stirred at 0°C for 15 min, the resulting mixture at 0°C was added 1- [4-(chloromethyl)phenyl]-3-[(4-chlorophenyl)methyl]urea (300.18 mg, 0.971 mmol, 1.20 equiv). The resulting mixture was stirred at r.t. for 2 h, quenched by MeOH (2 mL) at 0°C, concentrated under reduced pressure to afford 300 mg of tert-butyl 4-[[4-([[(4- chlorophenyl)methyl]carbamoyl]amino)phenyl]methyl]-3-oxopiperazine-1-carboxylate as a yellow solid. LCMS-ESI (POS.) m / z: 473 (M+H)+.

[0349] Compounds in the following table were prepared in a similar manner as tert-butyl 4-(4-(3-(4-chlorobenzyl)ureido)benzyl)-3-oxopiperazine-1-carboxylate, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 11 Synthesis of (S)-1-(4-chlorobenzyl)-3-(4-((3-methyl-2-oxopyrrolidin-1- yl)methyl)phenyl)urea (Compound 379) and (R)-1-(4-chlorobenzyl)-3-(4-((3-methyl-2- oxopyrrolidin-1-yl)methyl)phenyl)urea (Compound 380) [Image disponible dans le document PDF, Image available in the PDF document]

[0350] The racemic compound 1-[(4-chlorophenyl) methyl]-3-[4-[(3-methyl-2- oxopyrrolidin-1-yl) methyl] phenyl]urea (70 mg, 0.188 mmol, 1 equiv) was separated by Prep-Chiral-HPLC with the following conditions (Column: CHIRALPAK IF-2, 2*25cm, 5um; Mobile Phase A: Hex (8mmol / L NH3.MeOH)-HPLC, Mobile Phase B:EtOH--HPLC; Flow rate: 20 mL / min; Gradient: 20 B to 20 B in 35 min; Injection Volumn: 0.8 ml; Number Of Runs:6;) to afford 15.6mg of (S)-1-(4-chlorobenzyl)-3-(4-((3-methyl-2-oxopyrrolidin-1- yl)methyl)phenyl)urea and 19.1mg of (R)-1-(4-chlorobenzyl)-3-(4-((3-methyl-2- oxopyrrolidin-1-yl)methyl)phenyl)urea as white solids. N.B. Absolute stereochemistry assigned randomly and not confirmed. (S)-1-(4-chlorobenzyl)-3-(4-((3-methyl-2-oxopyrrolidin-1-yl)methyl)phenyl)urea. LCMS- ESI (POS.) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: 372 (M+H)+. <com:Sup>1< / com:Sup>H NMR (300 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>: 8.57 (s, 1H), 7.43 – 7.26 <com:Math><semantics>(m,5H),7.05(d,J=8.4Hz,2H),6.62(t,J=6.0Hz,1H),4.27(d,J=5.3Hz,4H),3.11(td,J=6.0Hz,1H),4.27(d,J=6.0Hz,1H),4.27(d,J=6.0Hz,4H),4.27(d,J=6.0Hz,4H),4.27(d,J=6.0Hz,4H),4.<annotation encoding="application / x-tex">(m, 5H), 7.05 (d, J = 8.4 Hz, 2H), 6.62 (t, J = 6.0 Hz, 1H), 4.27 (d, J = 5.3 Hz, 4H), 3.11 (td, J = 6.0 Hz, 1H), 4.27 (d, J = 6.0 Hz, 1H), 4.27 (d, J = 6.0 Hz, 4H), 4.27 (d, J = 6.0 Hz, 4H), 4.27 (d, J = 6.0 Hz, 4H), 4.< / annotation>< / semantics>< / com:Math> <com:Math><semantics>=6.4,3.0 Hz,2H),2.39 (q, J=8.6 Hz,1H),1.51 (dt, J=12.5,8.6 Hz,1H),1.23 (s, 2H),1.07<annotation encoding="application / x-tex">= 6.4, 3.0 \text{ Hz}, 2\text{H}), 2.39 \text{ (q, J} = 8.6 \text{ Hz}, 1\text{H}), 1.51 \text{ (dt, J} = 12.5, 8.6 \text{ Hz}, 1\text{H}), 1.23 \text{ (s, 2H)}, 1.07< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(d,J=7.1Hz,3H).<annotation encoding="application / x-tex">(d, J = 7.1 Hz, 3H).< / annotation>< / semantics>< / com:Math> (R)-1-(4-chlorobenzyl)-3-(4-((3-methyl-2-oxopyrrolidin-1-yl)methyl)phenyl)urea. LCMS-ESI (POS.) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: 372 (M+H)+. <com:Sup>1< / com:Sup>H NMR (300 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>: 8.59 (s, 1H), 7.43 <com:Math><semantics>−7.26<annotation encoding="application / x-tex">-7.26< / annotation>< / semantics>< / com:Math> (m, 5H), <com:Math><semantics>7.05<annotation encoding="application / x-tex">7.05< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>6.64<annotation encoding="application / x-tex">6.64< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>4.27<annotation encoding="application / x-tex">4.27< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=5.3<annotation encoding="application / x-tex">J = 5.3< / annotation>< / semantics>< / com:Math> Hz, 4H), <com:Math><semantics>3.38<annotation encoding="application / x-tex">3.38< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>3.16−3.06<annotation encoding="application / x-tex">3.16 - 3.06< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>2.39<annotation encoding="application / x-tex">2.39< / annotation>< / semantics>< / com:Math> (q, <com:Math><semantics>J=8.3<annotation encoding="application / x-tex">J = 8.3< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>1.49<annotation encoding="application / x-tex">1.49< / annotation>< / semantics>< / com:Math> (dd, <com:Math><semantics>J=12.4<annotation encoding="application / x-tex">J = 12.4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8.6<annotation encoding="application / x-tex">8.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 1.23 (s, 1H), 1.07 (d, <com:Math><semantics>J=7.2 Hz<annotation encoding="application / x-tex">J = 7.2 \text{ Hz}< / annotation>< / semantics>< / com:Math>, 3H).

[0351] Compounds in the following table were prepared in a similar manner as Compound 379 and Compound 380, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(R)−1−(4−chlorobenzyl)−3−(4−(((1,1−chlorobenzyl)−3−(4−(((1,1−chlorobenzyl)−3−(4−(((1,1−chlorobenzyl)−3−(4−(((1,1−chlorobenzyl)−3−(4−(((1,1−chlorobenzyl)−3−(4−(((1,1−chlorobenzyl)−3−(4−(((1,1−chlorobenzyl)−3−(4−(((1,1−chl<annotation encoding="application / x-tex">(R)-1-(4-chlorobenzyl)-3-(4-(((1,1-chlorobenzyl)-3-(4-(((1,1-chlorobenzyl)-3-(4-(((1,1-chlorobenzyl)-3-(4-(((1,1-chlorobenzyl)-3-(4-(((1,1-chlorobenzyl)-3-(4-(((1,1-chlorobenzyl)-3-(4-(((1,1-chlorobenzyl)-3-(4-(((1,1-chl< / annotation>< / semantics>< / com:Math> dioxidotetrahydrothiophen-3- yl)amino)methyl)phenyl)urea. LCMS-ESI (POS.) 370 Interme Chiralpa <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: 408 (M+H)+. <com:Sup>1< / com:Sup>H NMR (300 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) & diate k ID-2 <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>: 8.52 (s, 1H), 7.43 – 7.33 (m, 2H), 7.38 – 7.27 (m, 371 17.1 4H), <com:Math><semantics>7.18<annotation encoding="application / x-tex">7.18< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.5<annotation encoding="application / x-tex">J = 8.5< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>6.60<annotation encoding="application / x-tex">6.60< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>4.27<annotation encoding="application / x-tex">4.27< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=5.9<annotation encoding="application / x-tex">J = 5.9< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>3.69−3.53<annotation encoding="application / x-tex">3.69 - 3.53< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>3.39<annotation encoding="application / x-tex">3.39< / annotation>< / semantics>< / com:Math> (q, <com:Math><semantics>J=6.5 Hz<annotation encoding="application / x-tex">J = 6.5 \text{ Hz}< / annotation>< / semantics>< / com:Math>, 1H), <com:Math><semantics>3.29−3.14 (m, 3H)<annotation encoding="application / x-tex">3.29 - 3.14 \text{ (m, 3H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>3.09−2.93 (m, 3H)<annotation encoding="application / x-tex">3.09 - 2.93 \text{ (m, 3H)}< / annotation>< / semantics>< / com:Math> 1H), <com:Math><semantics>2.87<annotation encoding="application / x-tex">2.87< / annotation>< / semantics>< / com:Math> (dd, <com:Math><semantics>J=13.1<annotation encoding="application / x-tex">J = 13.1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>6.5<annotation encoding="application / x-tex">6.5< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>2.27−2.15<annotation encoding="application / x-tex">2.27 - 2.15< / annotation>< / semantics>< / com:Math> (m, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>2.10−1.91<annotation encoding="application / x-tex">2.10 - 1.91< / annotation>< / semantics>< / com:Math> (m, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>). <com:Math><semantics>(S)−1−(4−chlorobenzyl)−3−(4−(((1,1−chlorobenzyl))−3−(4−(((1,1−chlorobenzyl)))−3−(4−(((1,1−chlorobenzyl)))−3−(4−(((1,1−chlorobenzyl))))−3−(4−(((1,1−chlorobenzyl)))))<annotation encoding="application / x-tex">(S)-1-(4-chlorobenzyl)-3-(4-(((1,1-chlorobenzyl))-3-(4-(((1,1-chlorobenzyl)))-3-(4-(((1,1-chlorobenzyl)))-3-(4-(((1,1-chlorobenzyl))))-3-(4-(((1,1-chlorobenzyl)))))< / annotation>< / semantics>< / com:Math> dioxidotetrahydrothiophen-3- yl)amino)methyl)phenyl)urea. LCMS-ESI (POS.) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: 408 (M+H)+. <com:Sup>1< / com:Sup>H NMR (300 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>: 8.52 (s, 1H), 7.43 – 7.33 (m, 2H), 7.38 – 7.27 (m, 4H), <com:Math><semantics>7.18<annotation encoding="application / x-tex">7.18< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.5<annotation encoding="application / x-tex">J = 8.5< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>6.60<annotation encoding="application / x-tex">6.60< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>4.27<annotation encoding="application / x-tex">4.27< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=5.9<annotation encoding="application / x-tex">J = 5.9< / annotation>< / semantics>< / com:Math> Hz, <com:Math><semantics>2H<annotation encoding="application / x-tex">2H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>3.69−3.53<annotation encoding="application / x-tex">3.69 - 3.53< / annotation>< / semantics>< / com:Math> (m, <com:Math><semantics>2H<annotation encoding="application / x-tex">2H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>3.39<annotation encoding="application / x-tex">3.39< / annotation>< / semantics>< / com:Math> (q, <com:Math><semantics>J=6.5 Hz,1H,3.29−3.14 (m, 3H),3.09−2.93 (m, 3H)<annotation encoding="application / x-tex">J = 6.5 \text{ Hz}, 1\text{H}, 3.29 - 3.14 \text{ (m, 3H)}, 3.09 - 2.93 \text{ (m, 3H)}< / annotation>< / semantics>< / com:Math> 1H), <com:Math><semantics>2.87<annotation encoding="application / x-tex">2.87< / annotation>< / semantics>< / com:Math> (dd, <com:Math><semantics>J=13.1<annotation encoding="application / x-tex">J = 13.1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>6.5<annotation encoding="application / x-tex">6.5< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>2.27−2.15<annotation encoding="application / x-tex">2.27 - 2.15< / annotation>< / semantics>< / com:Math> (m, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>2.10−1.91<annotation encoding="application / x-tex">2.10 - 1.91< / annotation>< / semantics>< / com:Math> (m, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>). [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 12 Synthesis of 1-(4-methoxybenzyl)-3-(4-((4-methyl-2-oxopiperazin-1-yl)methyl)phenyl)urea. (Compound 384) Step 1: Prepration of 1-(4-methoxybenzyl)-3-(4-((2-oxopiperazin-1-yl)methyl)phenyl)urea (Intermediate 3-a): [Image disponible dans le document PDF, Image available in the PDF document]

[0352] To a stirred solution of tert-butyl 4-(4-(3-(4-methoxybenzyl)ureido)benzyl)-3- oxopiperazine-1-carboxylate (376 mg, 0.802 mmol, 1 equiv) in DCM was added TFA (1 mL). The resulting mixture was stirred at r.t. for 1h, concentrated under reduced pressure, and purified by C18 column chromatography, eluted with water(0.05%NH<com:Sub>4< / com:Sub>HCO<com:Sub>3< / com:Sub>) / ACN (2:1) to give a crude product, which was purified by Prep-HPLC with the following conditions (2#SHIMADZU (HPLC-01)): Column, XBridge Prep OBD C<com:Sub>18< / com:Sub> Column, 30x150mm 5um; mobile phase, Water(10MMOL / L NH4HCO3) and ACN (30% PhaseB up to 60% in 8 min); Detector, uv254nm to afford 60mg of 1-(4-methoxybenzyl)-3-(4-((2-oxopiperazin-1- yl)methyl)phenyl)urea (20.3 mg, 20%) as an off-white solid. LCMS-APCI (POS.) m / z: 369 <com:Math><semantics>(M+H)+.<annotation encoding="application / x-tex">(M+H)+.< / annotation>< / semantics>< / com:Math> Step 2: Prepration of 1-(4-methoxybenzyl)-3-(4-((4-methyl-2-oxopiperazin-1- yl)methyl)phenyl)urea (Intermediate 3-a): [Image disponible dans le document PDF, Image available in the PDF document]

[0353] To a solution of 3-[(4-methoxyphenyl)methyl]-1-[4-[(2-oxopiperazin-1- yl)methyl]phenyl]urea (35.00 mg, 0.095 mmol, 1.00 equiv) in DCE (3 mL) was added formaldehyde (68.40 mg, 0.760 mmol, 8.00 equiv). After stirred at r.t. for 10min, the mixture was added STAB (80.53 mg, 0.380 mmol, 4 equiv) and AcOH (22.82 mg, 0.380 mmol, 4 equiv). The resulting mixture was stirred at r.t. for 3 h. Water (20mL) was added and the mixture was extracted twice with EtOAc (20mL). The combined organic layers were washed twice with brine (20 mL), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, concentrated under reduced pressure, and purified by Prep-HPLC with the following conditions (2#SHIMADZU (HPLC- 01)): Column, XBridge Prep OBD C18 Column, 30*150mm 5um; mobile phase, Water (10mmol / L NH<com:Sub>4< / com:Sub>HCO<com:Sub>3< / com:Sub>) and ACN (18% Phase B up to 36% in 8 min); Detector, UV254nm to afford 6.3 mg of 1-(4-methoxybenzyl)-3-(4-((4-methyl-2-oxopiperazin-1- yl)methyl)phenyl)urea (17%) as a white solid. LCMS-APCI (POS.) m / z: 383 (M+H)+. <com:Sup>1< / com:Sup>H NMR (400 MHz, Methanol-<com:Math><semantics>d4<annotation encoding="application / x-tex">d_4< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.36 (d, <com:Math><semantics>J=8.5<annotation encoding="application / x-tex">J = 8.5< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.26 (d, <com:Math><semantics>J=8.7<annotation encoding="application / x-tex">J = 8.7< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.20 (d, <com:Math><semantics>J=8.7<annotation encoding="application / x-tex">J = 8.7< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.20 (d, <com:Math><semantics>J=8.7<annotation encoding="application / x-tex">J = 8.7< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.20 (d, <com:Math><semantics>J=8.7<annotation encoding="application / x-tex">J = 8.7< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.20 (d, <com:Math><semantics>J=8.7<annotation encoding="application / x-tex">J = 8.7< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.20 (d, <com:Math><semantics>J=8.7<annotation encoding="application / x-tex">J = 8.7< / annotation>< / semantics>< / com:Math> <com:Math><semantics>=8.5 Hz,2H<annotation encoding="application / x-tex">= 8.5 \text{ Hz}, 2\text{H}< / annotation>< / semantics>< / com:Math>), 6.90 (d, <com:Math><semantics>J=8.7 Hz,2H<annotation encoding="application / x-tex">J = 8.7 \text{ Hz}, 2\text{H}< / annotation>< / semantics>< / com:Math>), 4.55 (s, 2H), 4.32 (s, 2H), 3.79 (s, 3H), 3.32 <com:Math><semantics>−3.28<annotation encoding="application / x-tex">- 3.28< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(m,2H),3.17(s,2H),2.72−2.62(m,2H),2.34(s,3H).<annotation encoding="application / x-tex">(m, 2H), 3.17 (s, 2H), 2.72 - 2.62 (m, 2H), 2.34 (s, 3H).< / annotation>< / semantics>< / com:Math> Example 13 Synthesis of 1-(4-((8-oxa-3-azabicyclo[3.2.1]octan-3-yl)sulfonyl)phenyl)-3-(4- chlorobenzyl)urea. (Compound 526) Prepration of 1-(4-((8-oxa-3-azabicyclo[3.2.1]octan-3-yl)sulfonyl)phenyl)-3-(4- chlorobenzyl)urea. [Image disponible dans le document PDF, Image available in the PDF document]

[0354] To a stirred mixture of 4-({[(4-chlorophenyl)methyl]carbamoyl}amino)benzenesulfonyl chloride (100 mg, 0.278 mmol, 1.00 equiv) and TEA (84.6 mg, 0.836 mmol, 3.00 equiv) in DCM (1 mL) was added 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (41.6 mg, 0.278 mmol, 1.00 equiv). The resulting mixture was stirred at r.t. for 2 h, concentrated under reduced pressure, purified by Prep-HPLC with the following conditions (Column, XBridge Prep OBD C18 Column, 30*150 mm, 5μm; mobile phase, water(10 mmol / L NH<com:Sub>4< / com:Sub>HCO<com:Sub>3< / com:Sub>+0.1%NH<com:Sub>3< / com:Sub>.H<com:Sub>2< / com:Sub>O) and ACN (25% ACN up to 55% in 8 min)) to afford 20.8mg of 1-(4-((8-oxa-3-azabicyclo[3.2.1]octan-3-yl)sulfonyl)phenyl)-3-(4- chlorobenzyl)urea (17.14%) as a white solid. LCMS-APCI (POS.) m / z: 436 (M+H)+. <com:Sup>1< / com:Sup>H NMR (300 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.17 (s, 1H), 7.77 – 7.51 (m, 4H), 7.46 – 7.14 (m, 4H), 6.87 (t, J = <com:Math><semantics>6.0 Hz<annotation encoding="application / x-tex">6.0 \text{ Hz}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1H<annotation encoding="application / x-tex">1\text{H}< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>4.32 (t, J=5.0 Hz<annotation encoding="application / x-tex">4.32 \text{ (t, J} = 5.0 \text{ Hz}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>4H<annotation encoding="application / x-tex">4\text{H}< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>3.22 (d, J=11.1 Hz<annotation encoding="application / x-tex">3.22 \text{ (d, J} = 11.1 \text{ Hz}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2H<annotation encoding="application / x-tex">2\text{H}< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>2.54 (s, 2H)<annotation encoding="application / x-tex">2.54 \text{ (s, 2H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1.93−1.56 (m, 4H)<annotation encoding="application / x-tex">1.93 - 1.56 \text{ (m, 4H)}< / annotation>< / semantics>< / com:Math>.

[0355] Compounds in the following table were prepared in a similar manner as Compound 526, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 14 Synthesis of 1-(4-chlorobenzyl)-3-(4-(2-(pyridin-4-yloxy)ethyl)phenyl)urea. (Compound 485) Prepration of 1-(4-chlorobenzyl)-3-(4-(2-(pyridin-4-yloxy)ethyl)phenyl)urea. [Image disponible dans le document PDF, Image available in the PDF document]

[0356] To a solution of 1-(4-chlorobenzyl)-3-(4-(2-hydroxyethyl)phenyl)urea (Intermediate 38, 65 mg, 0.213 mmol, 1.0 equiv) in THF (1 mL) was added PPh<com:Sub>3< / com:Sub> (112 mg, 0.427 mmol, 2.0 equiv), pyridin-4-ol (41 mg, 0.427 mmol, 2.0 equiv) and diisopropyl azodicarboxylate (86 mg, 0.427 mmol, 2.0 equiv) sequentially. The reaction was stirred at 23 °C for 24 h. LC-MS showed generally half conversion. Then the reaction was concentrated and purified by preparative HPLC (H<com:Sub>2< / com:Sub>O (0.1% HCO<com:Sub>2< / com:Sub>H) / MeCN (0.1% HCO<com:Sub>2< / com:Sub>H) to yield 1-(4- chlorobenzyl)-3-(4-(2-(pyridin-4-yloxy)ethyl)phenyl)urea (7 mg, 9%). LCMS-ESI (POS.) m / z: 382.10 (M+H)<com:Sup>+< / com:Sup>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.53 (s, 1 H), 8.36 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 5.5 Hz, 2 H), 7.39 (d, <com:Math><semantics>J=8.5<annotation encoding="application / x-tex">J = 8.5< / annotation>< / semantics>< / com:Math> Hz, 2 H), 7.36–7.29 (m, 4 H), 7.17 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2 H), 6.96 (d, <com:Math><semantics>J=5.6<annotation encoding="application / x-tex">J = 5.6< / annotation>< / semantics>< / com:Math> Hz, 2 H), 6.61 (t, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 1 H), 4.28 (d, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 2 H), 4.23 (t, <com:Math><semantics>J=6.9<annotation encoding="application / x-tex">J = 6.9< / annotation>< / semantics>< / com:Math> Hz, 2 H), 2.96 (t, <com:Math><semantics>J=6.9 Hz,2 H<annotation encoding="application / x-tex">J = 6.9 \text{ Hz}, 2 \text{ H}< / annotation>< / semantics>< / com:Math>).

[0357] Compounds in the following table were prepared in a similar manner as Compound 485, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] Example 15 Synthesis of (R)-4-(3-(4-methoxybenzyl)ureido)-N-(1-(3-methylpyridin-2- yl)ethyl)benzamide. (Compound 513) Prepration of (R)-4-(3-(4-methoxybenzyl)ureido)-N-(1-(3-methylpyridin-2- yl)ethyl)benzamide. [Image disponible dans le document PDF, Image available in the PDF document]

[0358] To a vial charged with 4-(3-(4-methoxybenzyl)ureido)benzoic acid (Intermediate 1.4, 60 mg, 0.200 mmol, 1.0 equiv), (R)-1-(3-methylpyridin-2-yl)ethan-1-amine (33 mg, 0.240 mmol, 1.2 equiv), 3-(ethyliminomethyleneamino)-N,N-dimethyl-propan-1-amine (EDC) HCl salt (46 mg, 0.240 mmol, 1.2 equiv), and 4-DMAP (12 mg, 0.100 mmol, 0.5 equiv) was added DMF (1 mL) and diisopropylethylamine (76 mg, 0.600 mmol, 3.0 equiv). The reaction was stirred at 23 °C for 24 h. Then the crude mixture was directly subjected to preparative HPLC (H<com:Sub>2< / com:Sub>O (0.1% HCO<com:Sub>2< / com:Sub>H) / MeCN (0.1% HCO<com:Sub>2< / com:Sub>H) to yield (R)-4-(3-(4- methoxybenzyl)ureido)-N-(1-(3-methylpyridin-2-yl)ethyl)benzamide (22 mg, 22%) as a white solid.

[0359] Compounds in the following table were prepared in a similar manner as Compound 513, using the intermediates and reagents as listed. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Example 16 Synthesis of 1-(4-chlorobenzyl)-3-(4-(2-(pyridin-3-ylsulfonyl)ethyl)phenyl)urea. (Compound 487) Prepration of 1-(4-chlorobenzyl)-3-(4-(2-(pyridin-3-ylsulfonyl)ethyl)phenyl)urea. [Image disponible dans le document PDF, Image available in the PDF document]

[0360] To a solution of the 1-(4-(2-bromoethyl)phenyl)-3-(4-chlorobenzyl)urea (Intermediate 41, 30 mg, 0.082 mmol, 1.0 equiv) in DMF (1 mL) was added sodium pyridine-3-sulfinate (20 mg, 0.122 mmol, 1.5 equiv) as solid. The mixture was stirred at 60 °C for 22 h. Then the reaction was directly subjected to preparative HPLC (H<com:Sub>2< / com:Sub>O (0.1% HCO<com:Sub>2< / com:Sub>H) / MeCN (0.1% HCO<com:Sub>2< / com:Sub>H) to yield 1-(4- chlorobenzyl)-3-(4-(2-(pyridin-3-ylsulfonyl)ethyl)phenyl)urea (8 mg, 23%) as a white solid. LCMS- ESI (POS.) m / z: 430.1 (M+H)<com:Sup>+< / com:Sup>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.05 (d, <com:Math><semantics>J=2.3<annotation encoding="application / x-tex">J = 2.3< / annotation>< / semantics>< / com:Math> Hz, 1 H), 8.90 <com:Math><semantics>(dd,J=4.9,1.6Hz,1H),8.52(s,1H),8.30(dt,J=8.1,2.0Hz,1H),7.68(dd,J=8.0,4.8Hz,1H),<annotation encoding="application / x-tex">(dd, J = 4.9, 1.6 Hz, 1 H), 8.52 (s, 1 H), 8.30 (dt, J = 8.1, 2.0 Hz, 1 H), 7.68 (dd, J = 8.0, 4.8 Hz, 1 H),< / annotation>< / semantics>< / com:Math> 7.38 (d, <com:Math><semantics>J=8.5<annotation encoding="application / x-tex">J = 8.5< / annotation>< / semantics>< / com:Math> Hz, 2 H), 7.31 (d, <com:Math><semantics>J=8.5<annotation encoding="application / x-tex">J = 8.5< / annotation>< / semantics>< / com:Math> Hz, 2 H), 7.26 (d, <com:Math><semantics>J=8.5<annotation encoding="application / x-tex">J = 8.5< / annotation>< / semantics>< / com:Math> Hz, 2 H), 7.05 (d, <com:Math><semantics>J=8.5<annotation encoding="application / x-tex">J = 8.5< / annotation>< / semantics>< / com:Math> Hz, 2 H), 6.61 (t, <com:Math><semantics>J=5.9<annotation encoding="application / x-tex">J = 5.9< / annotation>< / semantics>< / com:Math> Hz, 1 H), 4.27 (t, <com:Math><semantics>J=5.5<annotation encoding="application / x-tex">J = 5.5< / annotation>< / semantics>< / com:Math> Hz, 2 H), 3.77–3.68 (m, 2 H), 2.89–2.79 (m, 2 H). Biological Example 1 NMN Fluoresence Biochemical and NAD Cellular Assay A. Human recombinant enzyme assay

[0213] Compounds described herein were assayed for their ability to stimulate the synthesis of nicotinamide mononucleotide (NMN) by the enzyme NAMPT. The human recombinant enzyme assay measures the activation of the enzyme activity by compounds using recombinant enzyme and substrates in a buffered cell-free system. The assay conditions closely mimic cellular environments. Dose responses were measured using an assay to detect the formation of nicotinamide mono-nucleotide. All experiments were performed in the 384-well format. Generally, 0.5 µL of DMSO containing varying concentrations of the test compound was mixed with 10 µL of the enzyme reagent solution. Enzyme reactions were initiated with the addition of 10 µL of a solution containing the substrates. The final assay conditions were as follows: 6 nM human NAMPT, 2.5 mM ATP, 20 μM PRPP and 150 μM nicotinamide in 50 mM HEPES, pH 7.2, 1 mM DTT, 1 mM CHAPS 50 mM NaCl, 100 mM MgCl<com:Sub>2< / com:Sub>. Following an incubation of 60 min at ambient temperature, 10 µL of 20% acetophenone in DMSO was added, followed by 10 μL of 2 M KOH and 40 μL of formic acid. The plates were read for fluorescence (Excitation / Emission = 355nm / 460nm) using an EnVision<com:Sup>TM< / com:Sup> plate reader after 40 mins of incubation at ambient temperature. The potency measurements for compounds, are quantified and represented as AC<com:Sub>1.4< / com:Sub> (the concentration of compounds that generates 40% higher activity over basal) and <com:Math><semantics>EC50<annotation encoding="application / x-tex">EC_{50}< / annotation>< / semantics>< / com:Math> (concentration of the compound that gives half-maximal activation). Comparative compounds A, B, C, and D were also tested, and the data are presented in Table A. For the <com:Math><semantics>AC1.4<annotation encoding="application / x-tex">AC_{1.4}< / annotation>< / semantics>< / com:Math> values, compounds designated with the letter "A" have <com:Math><semantics>AC1.4<annotation encoding="application / x-tex">AC_{1.4}< / annotation>< / semantics>< / com:Math> values that are less than 0.5 µM; compounds designated with the letter "B" have AC<com:Sub>1.4< / com:Sub> values that are between 0.5 μM and 2.5 μM; and compounds designated with the letter "C" have AC<com:Sub>1.4< / com:Sub> values that are greater than 2.5 <com:Math><semantics>μ<annotation encoding="application / x-tex">\mu< / annotation>< / semantics>< / com:Math>M. For example, compounds 36 and 242 have AC<com:Sub>1.4< / com:Sub> values of 0.15 and 0.42, respectively, and are designated as "A" in Table A, and compound 167 has an AC<com:Sub>1.4< / com:Sub> value of 0.78 and is designated as "B." As shown in Table A, comparator compound A, which has an unsubstituted phenyl ring (i.e., wherein R<com:Sup>1< / com:Sup> is hydrogen) is five to ten times less potent than compounds with a halo or methoxy substituent at the <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> position, as measured by <com:Math><semantics>AC1.4<annotation encoding="application / x-tex">AC_{1.4}< / annotation>< / semantics>< / com:Math>. Comparator A: [Image disponible dans le document PDF, Image available in the PDF document] Comparator B: [Image disponible dans le document PDF, Image available in the PDF document] Comparator C: [Image disponible dans le document PDF, Image available in the PDF document] Comparator D: [Image disponible dans le document PDF, Image available in the PDF document] Table A [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] B. Cellular NAD+ Modulation Assay.

[0362] The compounds described herein were also assayed for their ability to stimulate the endogenous NAMPT in a native cellular environment in the cellular NAD+ modulation assay, which measures the ability of the compound to modulate cellular NAD levels. Increased levels of NAD are expected by compounds that permeate the cells and activate the catalytic activity of the endogenous NAMPT.

[0363] Neuroblastoma SH-SY5Y cells were grown in 1:1 mixture of Eagle's Minimum Essential Medium and F12 Medium, along with 10% fetal bovine serum, in a humidified incubator with an atmosphere of 95% air and 5% CO2 at 37°C. The assays were initiated by plating 20 µL of SH-SY5Y cells in culture medium with 0.1% fetal bovine serum, at a density of 5000 cells per well to a 384-well Corning<com:Sup>TM< / com:Sup> BioCoat<com:Sup>TM< / com:Sup> Poly-D-Lysine Multiwell Plates. The plates were incubated in the 37°C incubators for a period of 5 hours. Compounds in DMSO were added to the plates in a volume of 120 nL using the Labcyte Echo Liquid Handlers. 5 μL of a 1.5 uM Doxorubicin solution in assay medium is added to each well. The plates are then incubated for 40 hours. 30 µL of a readout-solution containing 0.2 U / mL Diaphorase enzyme, 40 uM resazurin, 10 uM FMN, 0.8 U / mL Alcohol dehydrogenase, 3% ethanol, 0.4 mg / mL bovine serum albumin, 0.2% Triton<com:Sup>TM< / com:Sup> X-100 in 100 mM Tris-HCl, 30 mM EDTA, pH 8.4. The plates were read for fluorescence (Excitation / Emission = 540nm / 590nm) using an EnVision plate reader after 60 mins of incubation at ambient temperature. Table B shows the <com:Math><semantics>AC0.3<annotation encoding="application / x-tex">AC_{0.3}< / annotation>< / semantics>< / com:Math>, delta recovery, and EC<com:Sub>50< / com:Sub> data for the tested compounds Comparative compounds A, B, C, and D were also tested, and the data are presented in Table B. For the <com:Math><semantics>AC0.3<annotation encoding="application / x-tex">AC_{0.3}< / annotation>< / semantics>< / com:Math> values, compounds designated with the letter "A" have <com:Math><semantics>AC0.3<annotation encoding="application / x-tex">AC_{0.3}< / annotation>< / semantics>< / com:Math> values that are less than 0.5 <com:Math><semantics>μ<annotation encoding="application / x-tex">\mu< / annotation>< / semantics>< / com:Math>M; compounds designated with the letter "B" have <com:Math><semantics>AC0.3<annotation encoding="application / x-tex">AC_{0.3}< / annotation>< / semantics>< / com:Math> values that are between 0.5 <com:Math><semantics>μ<annotation encoding="application / x-tex">\mu< / annotation>< / semantics>< / com:Math>M and 2.5 <com:Math><semantics>μ<annotation encoding="application / x-tex">\mu< / annotation>< / semantics>< / com:Math>M; and compounds designated with the letter "C" have <com:Math><semantics>AC0.3<annotation encoding="application / x-tex">AC_{0.3}< / annotation>< / semantics>< / com:Math> values that are greater than 2.5 <com:Math><semantics>μ<annotation encoding="application / x-tex">\mu< / annotation>< / semantics>< / com:Math>M. For example, compound 36 has an <com:Math><semantics>AC0.3<annotation encoding="application / x-tex">AC_{0.3}< / annotation>< / semantics>< / com:Math> value of 0.15 and is designated as "A" in Table B, and compounds 167 and 242 have <com:Math><semantics>AC0.3<annotation encoding="application / x-tex">AC_{0.3}< / annotation>< / semantics>< / com:Math> values of 1.2 and 0.86, respectively, and are designated as "B." TABLE B. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Biological Example 2 Bidirectional Permeability through Caco-2 Monolayers

[0364] Caco-2 permeability was assessed for compounds described herein. As discussed previously, the Caco-2 permeability assay is commonly used to investigate human intestinal permeability and drug efflux and is an accurate predictor of in vivo absorption. Caco-2 cells (clone C2BBe1) were obtained from American Type Culture Collection (Manassas, VA). Cell monolayers were grown to confluence on collagen-coated, microporous membranes in 12- well assay plates. Details of the plates and their certification are shown below. The permeability assay buffer was Hanks' balanced salt solution containing 10 mM HEPES and 15 mM glucose at a pH of 7.4. The buffer in the receiver chamber also contained 1% bovine serum albumin. The dosing solution concentration was 5 µM for the test article in the assay buffer. Cell monolayers were dosed on the apical side (A-to-B) or basolateral side (B-to-A) and incubated at 37°C with 5% CO<com:Sub>2< / com:Sub> in a humidified incubator. Samples were taken from the donor and receiver chambers at 120 minutes. Each determination was performed in duplicate. The flux of co-dosed lucifer yellow was also measured for each monolayer to ensure no damage was inflicted to the cell monolayers during the flux period. All samples were assayed by LC-MS / MS (Waters ACQUITY UPLC® BEH Phenyl 30 × 2.1 mm, 1.7 μm) using electrospray ionization, using ammonium formate as the buffer (25 mM, pH 3.5).

[0365] The apparent permeability <com:Math><semantics>(Papp)<annotation encoding="application / x-tex">(P_{app})< / annotation>< / semantics>< / com:Math> and percent recovery were calculated as follows: [Image disponible dans le document PDF, Image available in the PDF document] (1) [Image disponible dans le document PDF, Image available in the PDF document] (2) Wherein: dCr / dt is the slope of the cumulative concentration in the receiver compartment versus time in μM s-1; <com:Math><semantics>Vr<annotation encoding="application / x-tex">V_r< / annotation>< / semantics>< / com:Math> is the volume of the receiver compartment in cm<com:Sup>3< / com:Sup>; <com:Math><semantics>Vd<annotation encoding="application / x-tex">V_d< / annotation>< / semantics>< / com:Math> is the volume of the donor compartment in cm<com:Sup>3< / com:Sup>; A is the area of the insert (1.13 cm<com:Sup>2< / com:Sup> for 12-well plates); C<com:Sub>A< / com:Sub> is the average of the nominal dosing concentration and the measured 120-minute donor concentration in µM; <com:Math><semantics>CN<annotation encoding="application / x-tex">C_N< / annotation>< / semantics>< / com:Math> is the nominal concentration of the dosing solution in <com:Math><semantics>μM<annotation encoding="application / x-tex">\mu M< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>Crfinal<annotation encoding="application / x-tex">C_r^{final}< / annotation>< / semantics>< / com:Math> is the cumulative receiver concentration in <com:Math><semantics>μM<annotation encoding="application / x-tex">\mu M< / annotation>< / semantics>< / com:Math> at the end of the incubation period; <com:Math><semantics>Cdfinal<annotation encoding="application / x-tex">C_d^{final}< / annotation>< / semantics>< / com:Math> is the concentration of the donor in <com:Math><semantics>μM<annotation encoding="application / x-tex">\mu M< / annotation>< / semantics>< / com:Math> at the end of the incubation period; and Efflux ratio (ER) is defined as P<com:Sub>app< / com:Sub> (B-to-A) / P<com:Sub>app< / com:Sub> (A-to-B).

[0366] Data for compounds tested are presented in Table C. Comparative compounds B, C, and D were also tested. As shown in the provided data, tested compounds having a halo or methoxy substituent at the R<com:Sup>1< / com:Sup> position demonstrate improved permeability compared with Comparator compounds B, C, and D. Comparator B: [Image disponible dans le document PDF, Image available in the PDF document] Comparator C: [Image disponible dans le document PDF, Image available in the PDF document] Comparator D: [Image disponible dans le document PDF, Image available in the PDF document] Table C.1 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Comparator E: [Image disponible dans le document PDF, Image available in the PDF document] Table C.2 [Image disponible dans le document PDF, Image available in the PDF document] Biological Example 3<com:Br / >Oral Pharmakokinetics

[0367] In vivo pharmacokinetics (PK) was assessed for compounds described herein in male C57BL / 6 mice and male Sprague Dawley rats. A. Pharmacokinetics of compounds in male C57BL / 6 mice following intravenous and oral administration

[0368] Pharmacokinetics of compounds were determined in male C57BL / 6 mice following a bolus IV dose at 1.0 mg / kg and a single PO dose at 1 mg / kg. Fifteen mice were used for each group in a sparse sampling design. Blood samples were taken up to 24 hr postdose. Concentrations in plasma were determined using a LC / MS / MS method.

[0369] Male C57BL / 6 mice were obtained from Charles River Laboratories (Hollister, CA). Animals were housed in polycarbonate cages in unidirectional air flow rooms on a 12 hr light / dark cycle. Animals were acclimated a minimum of three days prior to PK studies. Food (Lab Diet 5001 rodent diet) and water were available ad libitum during the acclimation period and during the study, except during study procedures. All in vivo experiments were performed in compliance with the IACUC protocol, appropriate guidelines of the test facility, and animal welfare regulations.

[0370] A group of 15 mice received 1.0 mg / kg of compound intravenously via injection into the tail vein. The IV dose volume was 5 mL / kg. The IV dose solution was prepared in 10% DMA / 20% PG / 70% HPβCD solution (40% w / v aqueous HPβCD) at a concentration of 0.2 mg / mL. Another group of 15 mice received the compounds by oral gavage at 1 mg / kg. The oral dose volume was 5 mL / kg. The oral dosing suspension was prepared by suspending the compound in 0.5% HPMC / 0.1% Tween<com:Sup>TM< / com:Sup> 80 in water at a concentration 0.2 mg / mL. Concentrations of IV and PO doses were measured at the end of the study. Pharmacokinetic parameters were calculated using the nominal dose values if the measured values were within 20% of the nominal values.

[0371] Sparse blood samples were collected from groups of three mice via retro-orbital bleeding, placed into a K<com:Sub>2< / com:Sub>EDTA microtainer tube and maintained on ice until centrifugation to obtain plasma. Each designated group of mice were bled at two-time points. The time points were predose (PO only), 5 (IV only), 15, 30 min, 1, 2, 4, 6, 8 and 24 hr postdose. Blood samples were centrifuged for 5 min at 14,000 rpm (20,800 g) in a refrigerated Eppendorf Model 5804 R centrifuge and the collected plasma was transferred to an Eppendorf<com:Sup>TM< / com:Sup> tube and stored at -80°C until analysis.

[0372] Plasma samples were analyzed for compound concentrations using an LC / MS / MS method as described below. Briefly, a 50 µL aliquot of each plasma sample was mixed with 100 μL of acetonitrile that contained compound as the internal standard (IS). The mixture was vortexed and centrifuged. The supernatant was transferred and filtered through a membrane (Pall Corporation, AcroPrep 96-well filter plate, 0.2 μm hydrophilic polypropylene membrane). Ten µL of the resulting solution was injected onto a reverse-phase C18 column and the resultant peaks detected on a SCIEX<com:Sup>TM< / com:Sup> API 4000 LC / MS / MS equipped with a turbo ionspray ionization source.

[0373] Following a bolus IV dose at 1.0 mg / kg, the mean plasma clearance (CL), volume of distribution (Vss), area under the curve (AUC) and elimination half-life (t½) was calculated or measured. Following a single oral dose at 1.0 mg / kg, the maximal plasma concentration (Cmax) and AUC∞ was measured or calculated. Oral bioavailability (%F) was calculated <com:Math><semantics>(%F=AUC(oral) / AUC(iv)×100)<annotation encoding="application / x-tex">(\%F=AUC(oral) / AUC(iv) \times 100)< / annotation>< / semantics>< / com:Math>.

[0374] Tables D-1 and D-2 show the PK parameters of compounds in male C57BL / 6 mice following an IV dose of the compounds at 1.0 mg / kg, wherein AUC<com:Sub>last< / com:Sub> stands for the area under the concentration-time curve from hour 0 to the last measurable concentration, <com:Math><semantics>AUC∞<annotation encoding="application / x-tex">AUC_{\infty}< / annotation>< / semantics>< / com:Math> stands for the area under the concentration-time curve extrapolated to infinity, CL is the apparent plasma clearance, V<com:Sub>ss< / com:Sub> is the apparent volume of distribution at steady state, and t<com:Sub>1 / 2< / com:Sub> is the time to maximum observed concentration. Table D-1 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Table D-2 [Image disponible dans le document PDF, Image available in the PDF document]

[0375] Tables E-1 and E-2 show the PK parameters of compounds in male C57BL / 6 mice following an oral dose of the compounds at 1.0 mg / kg, wherein C<com:Sub>max< / com:Sub> is the maximum observed concentration, t<com:Sub>max< / com:Sub> is the time to maximum observed concentration, AUC<com:Sub>last< / com:Sub> stands for the area under the concentration-time curve from hour 0 to the last measurable concentration, AUC∞ stands for the area under the concentration-time curve extrapolated to infinity, %F is the percentage of oral bioavailability, and t<com:Sub>1 / 2< / com:Sub> is the time to maximum observed concentration. Table E-1 [Image disponible dans le document PDF, Image available in the PDF document] Table E-2 [Image disponible dans le document PDF, Image available in the PDF document] B. Pharmacokinetics of compounds in male Sprague Dawley rats following intravenous and oral administration

[0376] Pharmacokinetics of compounds was studied in male Sprague Dawley rats following IV and PO administration. Three rats were used in each dose group. Serial blood samples were taken up to 24 hours post-dose. Concentrations of compound in plasma were determined using a LC / MS / MS method. The mean calculated pharmacokinetic parameters are summarized in Tables F and G.

[0377] Male Sprague Dawley rats with surgically implanted cannula at the jugular vein were obtained from Charles River Laboratories (Hollister, CA). All cannulae were locked using heparin dextrose solution. Animals were housed individually in polycarbonate cages in unidirectional air flow rooms on a 12 h light / dark cycle. Animals were acclimated a minimum of three days prior to PK studies. Food (Lab Diet 5001 rodent diet) and water were available ad libitum during the acclimation period and during the study, except during study procedures. All in vivo experiments were performed in compliance with the IACUC protocol, appropriate guidelines of the test facility (Cytokinetics, Inc), and animal welfare regulations.

[0378] Three rats were dosed IV via a bolus injection via the jugular vein cannula. Three rats were dosed by oral gavage. Vehicles for dosing were: (Vehicle A for IV studies) 10% DMA: 50% PG: 40% aqueous HPβCD; (Vehicle B for PO studies) was 0.5% HPMC / 0.1% Tween<com:Sup>™< / com:Sup> 80. Blood samples were collected in microtainer plasma tubes (K<com:Sub>3< / com:Sub>EDTA) from the jugular vein cannula at predose, 5 (IV only), 15, 30 min, 1, 2, 4, 6, and 24 h post-dose. Blood volumes were replaced with an equal amount of sterile 0.9% saline. Blood samples were centrifuged for 5 min at 14,000 rpm (20,800 g) in a refrigerated Eppendorf<com:Sup>™< / com:Sup> Model 5804 R centrifuge and the collected plasma was transferred to an Eppendorf<com:Sup>™< / com:Sup> tube and stored at -80°C for subsequent analysis.

[0379] The IV dose solution was prepared in 10% DMA / 50% PEG400 / 40% HPβCD solution (40% w / v aqueous HPβCD) at a concentration of 1 mg / mL. The oral dose suspension was prepared by suspending compound in 0.5% HPMC / 0.1% Tween<com:Sup>TM< / com:Sup> 80 in water. Concentrations of IV and PO doses were measured at the end of the study. Pharmacokinetic parameters were calculated using the nominal dose values if the measured values were within 20% of the nominal values.

[0380] Plasma samples were analyzed for compound concentrations using the LC / MS / MS method described below. Briefly, a 50 µL aliquot of each plasma sample was mixed with 100 µL of acetonitrile that contained compound as the internal standard. The mixture was vortexed and centrifuged. The supernatant was transferred and filtered through a membrane (Pall Corporation, AcroPrep 96-well filter plate, 0.2 µm hydrophilic polypropylene membrane). Ten µL of the resulting solution was injected onto a reverse-phase C18 column and the resultant peaks detected on a SCIEX API 4000 LC / MS / MS equipped with a turbo ionspray ionization source.

[0381] Following a bolus IV dose at 1.0 mg / kg, the mean plasma clearance (CL), volume of distribution (Vss), area under the curve (AUC) and elimination half-life (<com:Math><semantics>t12<annotation encoding="application / x-tex">t\frac{1}{2}< / annotation>< / semantics>< / com:Math>) was calculated or measured. Following a single oral dose at 1.0 mg / kg, the maximal plasma concentration (Cmax) and AUC∞ was measured or calculated. Oral bioavailability (%F) was calculated (%F=AUC(oral) / AUC(iv) x 100).

[0382] Table F shows the PK parameters of compounds in male Sprague Dawley rats following an IV dose of the compounds at 1.0 mg / kg, wherein AUC<com:Sub>last< / com:Sub> stands for the area under the concentration-time curve from hour 0 to the last measurable concentration, AUC∞ stands for the area under the concentration-time curve extrapolated to infinity, CL is the apparent plasma clearance, <com:Math><semantics>Vss<annotation encoding="application / x-tex">V_{ss}< / annotation>< / semantics>< / com:Math> is the apparent volume of distribution at steady state, and <com:Math><semantics>t12<annotation encoding="application / x-tex">t_{\frac{1}{2}}< / annotation>< / semantics>< / com:Math> is the time to maximum observed concentration. Table F [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document]

[0383] Table G shows the PK parameters of compounds in male Sprague Dawley rats following an oral dose of the compounds at <com:Math><semantics>1.0 mg / kg<annotation encoding="application / x-tex">1.0 \text{ mg / kg}< / annotation>< / semantics>< / com:Math>, wherein <com:Math><semantics>Cmax<annotation encoding="application / x-tex">C_{\text{max}}< / annotation>< / semantics>< / com:Math> is the maximum observed concentration, t<com:Sub>max< / com:Sub> is the time to maximum observed concentration, AUC<com:Sub>last< / com:Sub> stands for the area under the concentration-time curve from hour 0 to the last measurable concentration, AUC∞ stands for the area under the concentration-time curve extrapolated to infinity, %F is the percentage of oral bioavailability, and t<com:Sub>1 / 2< / com:Sub> is the time to maximum observed concentration. Table G [Image disponible dans le document PDF, Image available in the PDF document]

[0384] For both mice and rat studies, sample concentrations below the limit of quantification (BLQ) were treated as zero for pharmacokinetic calculations.

[0385] Composite pharmacokinetic parameters were estimated from a maximum of two sampling points per mouse and three mice per sampling point and the sparse data option of WinNonlin was used for noncompartmental analysis of the concentration-time data (Phoenix WinNonLin software, version 64; Pharsight, Mountain View, CA).

[0386] The elimination rate constant (k) was calculated as the absolute value of the slope of the linear regression of logarithm of the concentration versus time for the last three data points of the concentration-time profiles. Apparent elimination half-life <com:Math><semantics>(t1 / 2)<annotation encoding="application / x-tex">(t_{1 / 2})< / annotation>< / semantics>< / com:Math> values were calculated as ln(2) / k. Area under the concentration-time curve (AUC) values were estimated using linear trapezoidal method. AUC<com:Sub>last< / com:Sub> values were calculated from the dosing time to the last measurable concentration. AUC<com:Sub>∞< / com:Sub> values were calculated as the sum of the corresponding AUC<com:Sub>last< / com:Sub> and the ratio of the last detectable concentration divided by k. Plasma clearance (CL) was calculated from Dose / AUC∞. Volume of distribution at steady state (V<com:Sub>ss< / com:Sub>) was calculated from MRT<com:Sub>∞< / com:Sub> X CL. Maximum concentration (C<com:Sub>max< / com:Sub>) and time to reach C<com:Sub>max< / com:Sub> (t<com:Sub>max< / com:Sub>) were recorded as observed. Bioavailability was calculated AUC<com:Sub>\infty< / com:Sub>,po / AUC<com:Sub>\infty< / com:Sub> x 100% where AUC was the dose normalized AUC value. DEMANDE OU BREVET VOLUMINEUX LA PRÉSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND PLUS D'UN TOME. CECI EST LE TOME 2 DE 2 CONTENANT LES PAGES 324 À 596 NOTE: Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS / PATENTS THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE THAN ONE VOLUME THIS IS VOLUME 2 OF 2 CONTAINING PAGES 324 TO 596 NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME : NOTE POUR LE TOME / VOLUME NOTE:

Claims

1. A compound of Formula (II): [Image disponible dans le document PDF, Image available in the PDF document] (II), or a pharmaceutically acceptable salt thereof, wherein: R 1 is halo or methoxy; R 6 is hydrogen or halo; and p is 0 or 1, wherein when p is 1, R 2 R^2 is hydrogen or C 1 C_1 - C 6 C_6 alkyl; R 3 R^3 is hydrogen or C 1 C_1 - C 6 C_6 alkyl; R 4 is g) 5- to 10-membered heteroaryl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more independently selected C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl substituents, h) 3- to 10-membered heterocycloalkyl or heterocycloalkenyl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more substituents independently selected from the group consisting of halo, oxo, -OH, -CN, -C 1 - C 6 alkyl optionally substituted with one or more independently selected R y substituents, - C 1 -C 6 alkoxy optionally substituted with one or more independently selected halo substituents, − C ( O ) O C 1 − C 6 -C(O)OC_1-C_6 alkyl, − C ( O ) C 1 − C 6 -C(O)C_1-C_6 alkyl, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, − S ( O ) 2 − C 1 -S(O)_2-C_1 optionally substituted with one or more independently selected halo substituents, 3- to 6- membered heterocycloalkyl or heterocycloalkenyl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more independently selected oxo, 5- to 6-membered heteroaryl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more independently selected halo or - C 1 -C 6 alkyl substituents, and C 3 -C 6 cycloalkyl; wherein each R y is independently selected from the group consisting of halo, -OH, -CN, -C 1 -C 6 alkoxy, -C(O)NR q R r , C 6 -C 12 aryl, and 5- to 6-membered heteroaryl which contains 1 to 4 heteroatoms selected from N, O, and S; and each R q and R r is independently hydrogen or C 1 -C 6 alkyl; and R 5 is hydrogen or halo; and when p is 0 0 , R 4 R^4 is 1) 3- to 6-membered heterocycloalkyl or heterocycloalkenyl having exactly two annular heteroatoms, both of which are nitrogen atoms, wherein the 3- to 6-membered heterocycloalkyl or heterocycloalkenyl is substituted with one or more independently selected –C 1 -C 6 alkyl substituents and is optionally further substituted with one or more oxo substituents, m) 3- to 6-membered heterocycloalkyl or heterocycloalkenyl having exactly one annular heteroatom, which is an oxygen atom, wherein the 3- to 6-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo or – C 1 -C 6 alkyl substituents, n) 3- to 6-membered heterocycloalkyl or heterocycloalkenyl which contains 1 to 4 heteroatoms selected from N, O, and S and is substituted with one or more independently selected -S(O) 2 -C 1 -C 6 alkyl substituents and optionally further substituted with one or more independently selected oxo or -C 1 -C 6 alkyl substituents, 0) 5-membered heterocycloalkyl or heterocycloalkenyl having exactly two annular heteroatoms, one of which is a nitrogen atom and the other of which is an oxygen atom, wherein the 5-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo, C 1 C_1 - C 6 C_6 alkyl, or - S ( O ) 2 S(O)_2 -( C 1 C_1 - C 6 C_6 alkyl) substituents, p) 6-membered heterocycloalkyl or heterocycloalkenyl having exactly two annular heteroatoms, one of which is a sulfur atom and the other of which is a nitrogen atom, wherein the 6-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo, C 1 C_1 - C 6 C_6 alkyl, or -S(O) 2 -( C 1 C_1 - C 6 C_6 alkyl) substituents, q) 5-membered heteroaryl having exactly two annular heteroatoms, one of which is a nitrogen atom and the other of which is an oxygen atom, wherein the 5-membered heteroaryl is substituted with exactly one methyl substituent, r) 5-membered heteroaryl having exactly two annular heteroatoms, both of which are nitrogen atoms, wherein the 5-membered heteroaryl is substituted with one or more methyl substituents, s) 6-membered heteroaryl having one or two annular heteroatoms selected from N, O, and S, and optionally substituted with one or more methyl substituents, wherein the 6-membered [Image disponible dans le document PDF, Image available in the PDF document] heteroaryl is other than [Image disponible dans le document PDF, Image available in the PDF document] z) R 5 is hydrogen, provided that for the compound of Formula (II): (1) R 4 is other than 4-methylpiperazinyl, 4-phenylpiperazinyl, 4-pyridylpiperazinyl, 4- [Image disponible dans le document PDF, Image available in the PDF document] (furanylmethyl)piperazinyl, [Image disponible dans le document PDF, Image available in the PDF document] (2) the compound of Formula (II) is not [Image disponible dans le document PDF, Image available in the PDF document]2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R 1 is halo.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R 1 is Cl or F.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R 1 is methoxy.

5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein p is 1.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (II) is a compound of Formula (I-G): [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof, wherein: R 1 is halo or methoxy; R 2 R^2 is hydrogen or C 1 C_1 - C 6 C_6 alkyl; R 3 R^3 is hydrogen or C 1 C_1 - C 6 C_6 alkyl; R 4 is g) 5- to 10-membered heteroaryl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more independently selected C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl substituents, or h) 3- to 10-membered heterocycloalkyl or heterocycloalkenyl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more substituents independently selected from the group consisting of halo, oxo, -OH, -CN, - C 1 -C 6 alkyl optionally substituted with one or more independently selected R y substituents, -C 1 -C 6 alkoxy optionally substituted with one or more independently selected halo substituents, − C ( O ) O C 1 − C 6 -C(O)OC_1-C_6 alkyl, − C ( O ) C 1 − C 6 -C(O)C_1-C_6 alkyl, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, C 6 -C 12 aryl optionally substituted with one or more independently selected halo substituents, 3- to 6-membered heterocycloalkyl or heterocycloalkenyl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more independently selected oxo, 5- to 6-membered heteroaryl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more independently selected halo or -C 1 -C 6 alkyl substituents, and C 3 -C 6 cycloalkyl; wherein each R y is independently selected from the group consisting of halo, -OH, -CN, -C 1 -C 6 alkoxy, -C(O)NR q R r , C 6 -C 12 aryl, and 5- to 6-membered heteroaryl which contains 1 to 4 heteroatoms selected from N, O, and S; each R q and R r is independently hydrogen or C 1 -C 6 alkyl; R 5 is hydrogen or halo; and R 6 is hydrogen or halo, provided that (1) R 4 is other than 4-methylpiperazinyl, 4-phenylpiperazinyl, 4-pyridylpiperazinyl, 4- (furanylmethyl)piperazinyl ,and ; and [Image disponible dans le document PDF, Image available in the PDF document] (2) the compound of Formula (I-G) is not , [Image disponible dans le document PDF, Image available in the PDF document]7. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (II) is a compound of Formula (I): [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof, wherein: R 1 is halo or methoxy; R 2 R^2 is hydrogen or C 1 C_1 - C 6 C_6 alkyl; R 3 R^3 is hydrogen or C 1 C_1 - C 6 C_6 alkyl; R 4 is g) 5- to 10-membered heteroaryl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more independently selected C 1 -C 6 alkyl substituents, or h) 3- to 10-membered heterocycloalkyl or heterocycloalkenyl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more substituents independently selected from the group consisting of halo, oxo, -OH, -CN, -C 1 - C 6 alkyl optionally substituted with one or more independently selected R y substituents, - C 1 -C 6 alkoxy optionally substituted with one or more independently selected halo substituents, − C ( O ) O C 1 − C 6 -C(O)OC_1-C_6 alkyl, − C ( O ) C 1 − C 6 -C(O)C_1-C_6 alkyl, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, − S ( O ) 2 − C 1 -S(O)_2-C_1 optionally substituted with one or more independently selected halo substituents, 3- to 6- membered heterocycloalkyl or heterocycloalkenyl which contains 1 to 4 heteroatoms selected from N, O, and S, and 5- to 6-membered heteroaryl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more independently selected C 1 -C 6 alkyl substituents; wherein each R y is independently selected from the group consisting of halo, -OH, -CN, -C 1 -C 6 alkoxy, -C(O)NR q R r , C 6 -C 12 aryl, and 5- to 6-membered heteroaryl which contains 1 to 4 heteroatoms selected from N, O, and S; each R q and R r is independently hydrogen or C 1 -C 6 alkyl; R 5 is hydrogen; wherein (1) R 4 is other than 4-methylpiperazinyl, 4-phenylpiperazinyl, 4-pyridylpiperazinyl, 4- [Image disponible dans le document PDF, Image available in the PDF document] (furanylmethyl)piperazinyl, [Image disponible dans le document PDF, Image available in the PDF document] (2) the compound of Formula (I) is not / [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen.

9. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 2 R^2 is C 1 C_1 - C 6 C_6 alkyl.

10. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R 3 R^3 is hydrogen.

11. The compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R 3 R^3 is C 1 C_1 - C 6 C_6 alkyl.

12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R 4 is a 3- to 10-membered heterocycloalkyl or heterocycloalkenyl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more substituents independently selected from the group consisting of halo, oxo, -OH, -CN, - C 1 -C 6 alkyl optionally substituted with one or more independently selected R y substituents, -C 1 - C 6 alkoxy optionally substituted with one or more independently selected halo substituents, - C ( O ) O C 1 C(O)OC_1 - C 6 C_6 alkyl, − C ( O ) C 1 -C(O)C_1 - C 6 C_6 alkyl, − S ( O ) 2 -S(O)_2 - C 1 C_1 - C 6 C_6 alkyl, C 6 C_6 - C 12 C_{12} aryl optionally substituted with one or more independently selected halo substituents, 3- to 6-membered heterocycloalkyl or heterocycloalkenyl which contains 1 to 4 heteroatoms selected from N, O, and S, and 5- to 6- membered heteroaryl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more independently selected C 1 -C 6 alkyl substituents.

13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R 4 is a 4- to 6-membered heterocycloalkyl or heterocycloalkenyl which contains 1 to 4 heteroatoms selected from N, O, and S and is optionally substituted with one or more independently selected oxo, − S ( O ) 2 − C 1 − C 6 -S(O)_2-C_1-C_6 alkyl, or − C 1 − C 6 -C_1-C_6 alkyl optionally substituted with -OH.

14. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from the group consisting of [Image disponible dans le document PDF, Image available in the PDF document] ,15. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein R 4 is [Image disponible dans le document PDF, Image available in the PDF document]16. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R 4 is a 5- to 10 membered heteroaryl which contains 1 to 4 heteroatoms selected from N, O, and S optionally substituted with one or more independently selected C 1 -C 6 alkyl substituents.

17. The compound of any one of claims 1 to 11 and 16, or a pharmaceutically acceptable [Image disponible dans le document PDF, Image available in the PDF document] salt thereof, wherein R 4 is selected from the group consisting of , [Image disponible dans le document PDF, Image available in the PDF document] and18. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein p is 0.

19. The compound of any one of claims 1 to 4 and 18, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (II-A): [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof, wherein: R 1 is halo or methoxy; R 4 R^4 is 1) 3- to 6-membered heterocycloalkyl or heterocycloalkenyl having exactly two annular heteroatoms, both of which are nitrogen atoms, wherein the 3- to 6-membered heterocycloalkyl or heterocycloalkenyl is substituted with one or more independently selected –C 1 -C 6 alkyl substituents and is optionally further substituted with one or more oxo substituents, m) 3- to 6-membered heterocycloalkyl or heterocycloalkenyl having exactly one annular heteroatom, which is an oxygen atom, wherein the 3- to 6-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo or – C 1 -C 6 alkyl substituents, n) 3- to 6-membered heterocycloalkyl or heterocycloalkenyl which contains 1 to 4 heteroatoms selected from N, O, and S and is substituted with one or more independently selected -S(O) 2 -C 1 -C 6 alkyl substituents and optionally further substituted with one or more independently selected oxo or -C 1 -C 6 alkyl substituents, 0) 5-membered heterocycloalkyl or heterocycloalkenyl having exactly two annular heteroatoms, one of which is a nitrogen atom and the other of which is an oxygen atom, wherein the 5-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo, − C 1 -C_1 - C 6 C_6 alkyl, or − S ( O ) 2 -S(O)_2 - ( C 1 (C_1 - C 6 C_6 alkyl) substituents, p) 6-membered heterocycloalkyl or heterocycloalkenyl having exactly two annular heteroatoms, one of which is a sulfur atom and the other of which is a nitrogen atom, wherein the 6-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo, − C 1 -C_1 - C 6 C_6 alkyl, or − S ( O ) 2 -S(O)_2 - ( C 1 (C_1 - C 6 C_6 alkyl) substituents, q) 5-membered heteroaryl having exactly two annular heteroatoms, one of which is a nitrogen atom and the other of which is an oxygen atom, wherein the 5-membered heteroaryl is substituted with exactly one methyl substituent, r) 5-membered heteroaryl having exactly two annular heteroatoms, both of which are nitrogen atoms, wherein the 5-membered heteroaryl is substituted with one or more methyl substituents, s) 6-membered heteroaryl having one or two annular heteroatoms selected from N, O, and S, and optionally substituted with one or more methyl substituents, wherein the 6-membered [Image disponible dans le document PDF, Image available in the PDF document] heteroaryl is other than [Image disponible dans le document PDF, Image available in the PDF document] z) and R 6 is hydrogen or halo, provided that R 4 is other than 4-methylpiperazinyl, 4-phenylpiperazinyl, 4-pyridylpiperazinyl, 4- [Image disponible dans le document PDF, Image available in the PDF document] (furanylmethyl)piperazinyl,20. The compound of any one of claims 1 to 4, 18, and 19, or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from the group consisting of: 3- to 6-membered heterocycloalkyl or heterocycloalkenyl having exactly two annular heteroatoms, both of which are nitrogen atoms, wherein the 3- to 6-membered heterocycloalkyl or heterocycloalkenyl is substituted with one or more independently selected –C 1 -C 6 alkyl substituents and is optionally further substituted with one or more oxo substituents, 3- to 6-membered heterocycloalkyl or heterocycloalkenyl having exactly one annular heteroatom, which is an oxygen atom, wherein the 3- to 6-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo or – C 1 -C 6 alkyl substituents, 3- to 6-membered heterocycloalkyl or heterocycloalkenyl which contains 1 to 4 heteroatoms selected from N, O, and S and is substituted with one or more independently selected -S(O) 2 -C 1 -C 6 alkyl substituents and optionally further substituted with one or more independently selected oxo or -C 1 -C 6 alkyl substituents, 5-membered heterocycloalkyl or heterocycloalkenyl having exactly two annular heteroatoms, one of which is a nitrogen atom and the other of which is an oxygen atom, wherein the 5-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo, − C 1 -C_1 - C 6 C_6 alkyl, or − S ( O ) 2 -S(O)_2 - ( C 1 (C_1 - C 6 C_6 alkyl) substituents, and 6-membered heterocycloalkyl or heterocycloalkenyl having exactly two annular heteroatoms, one of which is a sulfur atom and the other of which is a nitrogen atom, wherein the 6-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo, − C 1 -C_1 - C 6 C_6 alkyl, or − S ( O ) 2 -S(O)_2 - ( C 1 (C_1 - C 6 C_6 alkyl) substituents.

21. The compound of any one of claims 1 to 4 and 18 to 20, or a pharmaceutically [Image disponible dans le document PDF, Image available in the PDF document] acceptable salt thereof, wherein R 4 is selected from the group consisting of [Image disponible dans le document PDF, Image available in the PDF document]22. The compound of any one of claims 1 to 4 and 18 to 20, or a pharmaceutically acceptable salt thereof, wherein R 4 is 3- to 6-membered heterocycloalkyl or heterocycloalkenyl having exactly two annular heteroatoms, both of which are nitrogen atoms, wherein the 3- to 6-membered heterocycloalkyl or heterocycloalkenyl is substituted with one or more independently selected –C 1 -C 6 alkyl substituents and is optionally further substituted with one or more oxo substituents, or 6-membered heterocycloalkyl or heterocycloalkenyl having exactly two annular heteroatoms, one of which is a sulfur atom and the other of which is a nitrogen atom, wherein the 6-membered heterocycloalkyl or heterocycloalkenyl is optionally substituted with one or more independently selected oxo, − C 1 -C_1 - C 6 C_6 alkyl, or − S ( O ) 2 -S(O)_2 - ( C 1 (C_1 - C 6 C_6 alkyl) substituents.

23. The compound of any one of claims 1 to 4 and 18 to 22, or a pharmaceutically [Image disponible dans le document PDF, Image available in the PDF document] acceptable salt thereof, wherein R 4 is24. The compound of any one of claims 1 to 4, 18, and 19, or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from the group consisting of: 5-membered heteroaryl having exactly two annular heteroatoms, one of which is a nitrogen atom and the other of which is an oxygen atom, wherein the 5-membered heteroaryl is substituted with exactly one methyl substituent, 5-membered heteroaryl having exactly two annular heteroatoms, both of which are nitrogen atoms, wherein the 5-membered heteroaryl is substituted with one or more methyl substituents, and 6-membered heteroaryl having one or two annular heteroatoms selected from N, O, and S, and optionally substituted with one or more methyl substituents, wherein the 6-membered [Image disponible dans le document PDF, Image available in the PDF document] heteroaryl is other than25. The compound of any one of claims 1 to 4, 18, 19, and 24, or a pharmaceutically [Image disponible dans le document PDF, Image available in the PDF document] acceptable salt thereof, wherein R 4 is selected from the group consisting of [Image disponible dans le document PDF, Image available in the PDF document]26. The compound of any one of claims 1 to 4, 18, and 19, or a pharmaceutically acceptable [Image disponible dans le document PDF, Image available in the PDF document] salt thereof, wherein R 4 is27. A compound selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof.

28. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document]29. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document] 64930. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is [Image disponible dans le document PDF, Image available in the PDF document]31. A pharmaceutical composition comprising a compound of any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

32. Use of a compound of any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a disease or condition mediated by NAMPT activity in a subject in need thereof.

33. Use of a compound of any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, for treating a disease or condition mediated by NAMPT activity in a subject in need thereof.

34. Use of a pharmaceutical composition of claim 31 for treating a disease or condition mediated by NAMPT activity in a subject in need thereof.

35. Use of a pharmaceutical composition of claim 31 for treating a disease or condition mediated by NAMPT activity in a subject in need thereof.

36. The use of any one of claims 32 to 35, wherein the disease or condition is selected from the group consisting of cancer, a hyperproliferative disease or condition, an inflammatory disease or condition, a metabolic disorder, a cardiac disease or condition, chemotherapy induced tissue damage, a renal disease, a neurological disease or injury, a neurodegenerative disorder or disease, diseases caused by impaired stem cell function, diseases caused by DNA damage, primary mitochondrial disorders, and a muscle disease.

37. The use of any one of claims 32 to 35, wherein the disease or condition is selected from the group consisting of obesity, atherosclerosis, insulin resistance, cardiovascular disease, heart failure, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, depression, Down syndrome, aging, axonal degeneration, carpal tunnel syndrome, Guillain-Barre syndrome, nerve damage, and polio (poliomyelitis).

38. The use of any one of claims 32 to 35, wherein the disease or condition is selected from the group consisting of a metabolic disease, type 2 diabetes, heart failure with preserved ejection fraction, neonatal nerve injury, spinal cord injury, and a muscle wasting disorder.

39. A compound of any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, for use in treating a disease or condition mediated by NAMPT activity in a subject in need thereof.

40. The compound, or a pharmaceutically acceptable salt thereof, for use of claim 39, wherein the disease or condition is selected from the group consisting of cancer, a hyperproliferative disease or condition, an inflammatory disease or condition, a metabolic disorder, a cardiac disease or condition, chemotherapy induced tissue damage, a renal disease, a neurological disease or injury, a neurodegenerative disorder or disease, diseases caused by impaired stem cell function, diseases caused by DNA damage, primary mitochondrial disorders, and a muscle disease.

41. The compound, or a pharmaceutically acceptable salt thereof, for use of claim 39, wherein the disease or condition is selected from the group consisting of obesity, atherosclerosis, insulin resistance, cardiovascular disease, heart failure, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, depression, Down syndrome, aging, axonal degeneration, carpal tunnel syndrome, Guillain-Barre syndrome, nerve damage, and polio (poliomyelitis).

42. The compound, or a pharmaceutically acceptable salt thereof, for use of claim 39, wherein the disease or condition is selected from the group consisting of a metabolic disease, type 2 diabetes, heart failure with preserved ejection fraction, neonatal nerve injury, spinal cord injury, and a muscle wasting disorder.

43. A pharmaceutical composition of claim 31, for use in treating a disease or condition mediated by NAMPT activity in a subject in need thereof.

44. The pharmaceutical composition for use of claim 43, wherein the disease or condition is selected from the group consisting of cancer, a hyperproliferative disease or condition, an inflammatory disease or condition, a metabolic disorder, a cardiac disease or condition, chemotherapy induced tissue damage, a renal disease, a neurological disease or injury, a neurodegenerative disorder or disease, diseases caused by impaired stem cell function, diseases caused by DNA damage, primary mitochondrial disorders, and a muscle disease.

45. The pharmaceutical composition for use of claim 43, wherein the disease or condition is selected from the group consisting of obesity, atherosclerosis, insulin resistance, cardiovascular disease, heart failure, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, depression, Down syndrome, aging, axonal degeneration, carpal tunnel syndrome, Guillain-Barre syndrome, nerve damage, and polio (poliomyelitis).

46. The pharmaceutical composition for use of claim 43, wherein the disease or condition is selected from the group consisting of a metabolic disease, type 2 diabetes, heart failure with preserved ejection fraction, neonatal nerve injury, spinal cord injury, and a muscle wasting disorder.